View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMATION - USD ($)	Apr. 01, 2017	May 19, 2017	Oct. 01, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--04-01
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Apr. 01, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,464,290
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,866,084,197

CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Income Statement [Abstract]
Net revenues	$ 886,116,000	$ 908,832,000	$ 910,373,000
Cost of goods sold	507,622,000	502,918,000	475,955,000
Gross profit	378,494,000	405,914,000	434,418,000
Operating expenses:
Research and development	37,556,000	44,965,000	54,187,000
Selling, general and administrative	301,726,000	317,223,000	337,168,000
Impairment of assets	58,593,000	92,395,000	5,441,000
Contingent consideration income	0	(4,727,000)	(2,918,000)
Total operating expenses	397,875,000	449,856,000	393,878,000
Operating (loss) income	(19,381,000)	(43,942,000)	40,540,000
Other expense, net	(8,095,000)	(9,474,000)	(9,375,000)
(Loss) income before (benefit) provision for income taxes	(27,476,000)	(53,416,000)	31,165,000
(Benefit) provision for income taxes	(1,208,000)	2,163,000	14,268,000
Net (loss) income	$ (26,268,000)	$ (55,579,000)	$ 16,897,000
Net (loss) income per share - basic (in dollars per share)	$ (0.51)	$ (1.09)	$ 0.33
Net (loss) income per share - diluted (in dollars per share)	$ (0.51)	$ (1.09)	$ 0.32
Weighted average shares outstanding
Basic (in shares)	51,524	50,910	51,533
Diluted (in shares)	51,524	50,910	52,089

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (26,268)	$ (55,579)	$ 16,897
Other comprehensive income (loss):
Impact of defined benefit plans, net of tax	5,220	1,431	(4,331)
Foreign currency translation adjustment	(7,336)	(1,987)	(23,710)
Unrealized (loss) gain on cash flow hedges, net of tax	(364)	(3,938)	11,371
Reclassifications into earnings of cash flow hedge losses (gains), net of tax	4,647	(8,822)	(6,464)
Other comprehensive income (loss)	2,167	(13,316)	(23,134)
Comprehensive loss	$ (24,101)	$ (68,895)	$ (6,237)

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Current assets:
Cash and cash equivalents	$ 139,564	$ 115,123
Accounts receivable, less allowance of $2,184 at April 1, 2017 and $2,253 at April 2, 2016	152,683	157,093
Inventories, net	176,929	187,028
Prepaid expenses and other current assets	40,853	28,842
Total current assets	510,029	488,086
Property, plant and equipment, net	323,862	337,634
Intangible assets, less accumulated amortization of $215,772 at April 1, 2017 and $190,816 at April 2, 2016	177,540	204,458
Goodwill	210,841	267,840
Deferred tax asset, long term	3,988	7,055
Other long-term assets	12,449	14,055
Total assets	1,238,709	1,319,128
Current liabilities:
Notes payable and current maturities of long-term debt	61,022	43,471
Accounts payable	42,973	39,674
Accrued payroll and related costs	43,534	35,798
Other current liabilities	63,650	66,608
Total current liabilities	211,179	185,551
Long-term debt, net of current maturities	253,625	364,529
Long-term deferred tax liability	12,114	21,377
Other long-term liabilities	22,181	26,106
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 52,255,495 shares at April 1, 2017 and 50,932,348 shares at April 2, 2016	523	509
Additional paid-in capital	482,044	439,912
Retained earnings	289,916	316,184
Accumulated other comprehensive loss	(32,873)	(35,040)
Total stockholders’ equity	739,610	721,565
Total liabilities and stockholders’ equity	$ 1,238,709	$ 1,319,128

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,184	$ 2,253
Intangible assets, accumulated amortization	$ 215,772	$ 190,816
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	52,255,495	50,932,348
Common stock, outstanding (in shares)	52,255,495	50,932,348

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
Balance, value at Mar. 29, 2014	$ 837,888	$ 520	$ 402,611	$ 433,347	$ 1,410
Balance, shares (in shares) at Mar. 29, 2014		52,041
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,763	$ 2	4,761
Employee stock purchase plan (in shares)		183
Exercise of stock options and related tax benefit	14,645	$ 5	14,640
Exercise of stock options and related tax benefit (in shares)		500
Shares repurchased	(39,033)	$ (11)	(9,143)	(29,879)
Shares repurchased (in shares)		(1,174)
Issuance of restricted stock, net of cancellations	1	$ 1
Share-based Compensation	14,095
Issuance of restricted stock, net of cancellations (in shares)		121
Stock-based compensation expense	14,095		14,095
Net (loss) income	16,897
Other comprehensive income	(23,134)
Balance, value at Mar. 28, 2015	826,122	$ 517	426,964	420,365	(21,724)
Balance, shares (in shares) at Mar. 28, 2015		51,671
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,341	$ 1	4,340
Employee stock purchase plan (in shares)		145
Exercise of stock options and related tax benefit	14,032	$ 6	14,026
Exercise of stock options and related tax benefit (in shares)		492
Shares repurchased	(60,984)	$ (15)	(12,367)	(48,602)
Shares repurchased (in shares)		(1,488)
Issuance of restricted stock, net of cancellations	0	$ 0
Share-based Compensation	6,949
Issuance of restricted stock, net of cancellations (in shares)		112
Stock-based compensation expense	6,949		6,949
Net (loss) income	(55,579)
Other comprehensive income	(13,316)
Balance, value at Apr. 02, 2016	721,565	$ 509	439,912	316,184	(35,040)
Balance, shares (in shares) at Apr. 02, 2016		50,932
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	3,559	$ 2	3,557
Employee stock purchase plan (in shares)		141
Exercise of stock options and related tax benefit	29,437	$ 12	29,425
Exercise of stock options and related tax benefit (in shares)		1,048
Issuance of restricted stock, net of cancellations	0
Share-based Compensation	9,150
Issuance of restricted stock, net of cancellations (in shares)		134
Stock-based compensation expense	9,150		9,150
Net (loss) income	(26,268)
Other comprehensive income	2,167
Balance, value at Apr. 01, 2017	$ 739,610	$ 523	$ 482,044	$ 289,916	$ (32,873)
Balance, shares (in shares) at Apr. 01, 2017		52,255

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Cash Flows from Operating Activities:
Net (loss) income	$ (26,268)	$ (55,579)	$ 16,897
Non-cash items:
Depreciation and amortization	89,733	89,911	86,053
Impairment of assets	75,348	101,243	5,877
Stock-based compensation expense	9,150	6,949	14,095
Deferred tax (benefit) expense	(6,800)	(1,038)	4,230
Unrealized loss (gain) from hedging activities	517	(2,645)	1,558
Changes in fair value of contingent consideration	0	(4,727)	(2,918)
Provision for losses on accounts receivable and inventory	11,381	13,053	4,972
Other non-cash operating activities	860	899	1,055
Change in operating assets and liabilities:
Change in accounts receivable	3,155	(10,328)	8,446
Change in inventories	(1,552)	11,896	(21,515)
Change in prepaid income taxes	1,395	(651)	10,662
Change in other assets and other liabilities	(18,253)	3,121	(8,013)
Tax benefit of exercise of stock options	0	0	3,786
Change in accounts payable and accrued expenses	21,072	(30,239)	1,993
Net cash provided by operating activities	159,738	121,865	127,178
Cash Flows from Investing Activities:
Capital expenditures	(76,135)	(102,405)	(122,220)
Proceeds from sale of property, plant and equipment	2,822	637	452
Other acquisitions and investments	0	(3,000)	0
Net cash used in investing activities	(73,313)	(104,768)	(121,768)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	0	(943)	(1,048)
Net (decrease) increase in short-term loans	(50,727)	2,272	843
Repayment of term loan borrowings	(42,683)	(21,342)	(8,531)
Proceeds from employee stock purchase plan	3,560	4,341	4,763
Proceeds from exercise of stock options	29,437	14,032	9,290
Share repurchases	0	(60,984)	(39,033)
Other financing activities	0	0	556
Net cash used in financing activities	(60,413)	(62,624)	(33,160)
Effect of exchange rates on cash and cash equivalents	(1,571)	(12)	(4,057)
Net Change in Cash and Cash Equivalents	24,441	(45,539)	(31,807)
Cash and Cash Equivalents at Beginning of Year	115,123	160,662	192,469
Cash and Cash Equivalents at End of Year	139,564	115,123	160,662
Supplemental Disclosures of Cash Flow Information:
Interest paid	7,850	8,511	8,497
Income taxes paid	6,957	7,829	11,211
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 6,255	$ 9,663	$ 7,458

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	Apr. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions to customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. Blood and its components (plasma, platelets, and red cells) have many vital - and frequently life-saving - clinical applications. Plasma is used for patients with major blood loss and is manufactured into biopharmaceuticals to treat a variety of illnesses, including immune diseases and coagulation disorders. Red cells treat trauma patients or patients undergoing surgery with high blood loss, such as open heart surgery or organ transplant. Platelets have many uses in patient care, including supporting cancer patients undergoing chemotherapy. Blood is essential to a modern healthcare system. Haemonetics develops and markets a wide range of devices and solutions to serve our customers. We provide plasma collection systems and software which enable plasma fractionators to make life saving pharmaceuticals. We provide analytical devices for measuring hemostasis which enable healthcare providers to better manage their patients’ bleeding risk. Haemonetics makes blood processing systems and software which make blood donation more efficient and track life giving blood components. Finally, Haemonetics supplies systems and software which facilitate blood transfusions and cell processing. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The accompanying consolidated financial statements present separately our financial position, results of operations, cash flows, and changes in shareholders’ equity. All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. Operating results for fiscal 2017 include an overstatement of inventory related charges due to the correction of capitalized manufacturing variances and corrections of certain out of period items. Absent these corrections, our operating loss for the fiscal year ended April 1, 2017 would have been $2.4 million lower than the amount included in the accompanying consolidated statements of (loss) income and comprehensive loss. Operating results for fiscal 2016 include the correction of an overstated liability in fiscal 2014, the correction of capitalized manufacturing variances identified during fiscal 2017 and corrections of certain other out of period items, all of which were determined to be immaterial to all periods impacted. Absent these corrections, our net loss for the fiscal year ended April 2, 2016 would have been $3.5 million higher than the amount included in the accompanying consolidated statements of (loss) income and comprehensive loss. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Refer to Note 19, Subsequent Events, for information pertaining to the sale of a product line which occurred after the balance sheet date but prior to the issuance of the financial statements. There were no other material subsequent events identified.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Apr. 01, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal 2017 and 2015 include 52 weeks with each quarter having 13 weeks. Fiscal 2016 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions. We consider estimates to be critical if we are required to make assumptions about material matters that are uncertain at the time of estimation or if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: revenue recognition, allowance for doubtful accounts, inventory provisions, intangible asset and goodwill valuation, legal and other judgmental accruals, and income taxes.

Reclassifications

Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.

Contingencies

We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, employee related litigation, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a loss is probable and a range of loss is established but a best estimate cannot be made, we record the minimum loss contingency amount, which could be zero. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. As information becomes known, an additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount.

Revenue Recognition

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer, and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.

We offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum potential rebate or discount that could be earned. In circumstances where we provide upfront rebate payments to customers, we capitalize the rebate payments and amortize the resulting asset as a reduction of revenue using a systematic method over the life of the contract.

Product Revenues

Product sales consist of the sale of our disposable blood component collection and processing sets and the related equipment. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product. We also place equipment at customer sites. While we retain ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. We recover the cost of providing the equipment from the sale of disposables.

Software Revenues

We offer a variety of software solutions to support our plasma, blood collection and hospital customers. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. For hospitals, we provide solutions to help improve patient safety, reduce cost and ensure compliance.

Our software revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.

We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.

Non-Income Taxes

We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.

We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses. In December 2015, this tax was suspended for two years, beginning on January 1, 2016. This tax may be imposed again beginning on January 1, 2018, unless the suspension is extended or the medical device excise tax is permanently repealed.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of (loss) income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss on the consolidated balance sheet.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of April 1, 2017, our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds.

Allowance for Doubtful Accounts

We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience.

Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. We have based our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. Significant changes in the timing or level of demand for our products results in recording additional provisions for excess, expired and obsolete inventory. Additionally, uncertain timing of next-generation product approvals, variability in product launch strategies, non-cancelable purchase commitments, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:



Asset Classification		Estimated Useful Lives
Building		30-40 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		2-10 Years
Haemonetics equipment		3-7 Years

We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for disposables used with these devices, from which we generate revenues. We also consider product life cycle in our evaluation of useful life and recoverability. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results.

Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the consolidated statements of (loss) income.

Goodwill and Intangible Assets

Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("Topic 350"), or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units.

In fiscal 2017, we early adopted ASU No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment. Under this amendment, entities perform their goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. We determine our reporting units by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. We aggregate components within an operating segment that have similar economic characteristics. Our reporting units for purposes of assessing goodwill impairment are organized primarily based on operating segments and geography and include: (a) North America Plasma, (b) North America Blood Center, (c) North America Hospital, (d) Europe, Middle East, and Africa (collectively "EMEA"), (e) Asia-Pacific and (f) Japan. In the prior period, North America Blood Center and North America Hospital were components of a single reporting unit, Americas Blood Center and Hospital. During the fourth quarter of fiscal 2017, we completed certain organizational changes which resulted in the disaggregation of Americas Blood Center and Hospital into two separate reporting units. The goodwill associated with the legacy Americas Blood Center and Hospital reporting unit was allocated to the North America Blood Center and North America Hospital reporting units based on their relative fair values. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due to the size and scale of the Plasma business unit.

When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

In fiscal 2017 and 2016, we used the income approach, specifically the discounted cash flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. We selected this method as being the most meaningful in preparing our goodwill assessments because the use of the income approach typically generates a more precise measurement of fair value than the market approach. In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our discounted cash flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our discounted cash flow analysis and reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test.

During the fourth quarter of fiscal 2017, we performed our annual goodwill impairment test under the guidelines of ASU No. 2017-04. The results of the goodwill impairment test performed indicated that the estimated fair value of all of our reporting units exceeded their respective carrying values, with the exception of North America Blood Center, for which we recorded an impairment charge of $57.0 million, which represented the entire goodwill balance associated with this reporting unit. There were no other reporting units at risk of impairment as of the fiscal 2017 annual test date.

During fiscal 2016, we recorded a goodwill impairment charge of $66.3 million associated with the EMEA reporting unit. At the time the impairment assessment was performed, this represented the entire goodwill balance of this reporting unit. During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of the All Other operating segment became components of the EMEA operating segment. As a result, we transferred $20.5 million of goodwill to the EMEA operating segment, which represented the portion of the goodwill associated with these components. Refer to Note 5, Goodwill and Intangible Assets, for additional details regarding the goodwill impairments recorded.

We review intangible assets subject to amortization for impairment at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products.

When an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified.

We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

During fiscal 2017, 2016 and 2015, we determined that there were potential impairment indicators for certain intangible assets subject to amortization. As such, we performed the recoverability test described above for the relevant asset groups. In fiscal 2017 and 2016, we determined that the undiscounted cash flows did not support the carrying value of certain identified asset groups and made the decision to discontinue the use of and investment in these assets. Accordingly, we recorded impairment charges of $4.8 million and $25.8 million, respectively, in fiscal 2017 and 2016. The impairment charges in fiscal 2017 consisted of non-core and underperforming assets while the $25.8 million of impairment charges recorded in fiscal 2016 consisted of $18.7 million related to the write down of the SOLX intangible assets and $7.1 million related to intangible assets that were identified as part of the Company's global strategic review. In fiscal 2015, we determined that the expected undiscounted cash flows exceeded the carrying value of the asset groups identified. See Note 5, Goodwill and Intangible Assets, to our consolidated financial statements contained in Item 8 for additional information.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of five to 10 years. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. We capitalize costs associated with both software that we sell as a separate product and software that is embedded in a device.

We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. During fiscal 2017 and fiscal 2016, we recorded $4.0 million and $6.0 million, respectively, of impairment charges related to the discontinuance of certain capitalized software projects. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.

Other Current Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	April 1, 2017		April 2, 2016
VAT liabilities	$	4,051	$	1,289
Forward contracts	966		4,210
Deferred revenue	26,485		27,053
Accrued taxes	4,407		3,876
All other	27,741		30,180
Total	$	63,650	$	66,608

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	April 1, 2017		April 2, 2016
Unfunded pension liability	14,060		18,067
Unrecognized tax benefit	1,627		2,283
All other	6,494		5,756
Total	$	22,181	$	26,106

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of (loss) income. Advertising expenses were $2.5 million, $3.9 million, and $4.5 million in fiscal 2017, 2016 and 2015, respectively.

Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.

Income Taxes

The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable. All available evidence, both positive and negative, has been considered to determine whether, based on the weight of that evidence, a valuation allowance is needed against the deferred tax assets. Significant weight has been given to our consolidated worldwide cumulative loss position for the current and prior two years.

We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.

We evaluate at the end of each reporting period whether some or all of the undistributed earnings of our foreign subsidiaries are permanently reinvested. We recognize deferred income tax liabilities to the extent that management asserts that undistributed earnings of its foreign subsidiaries are not permanently reinvested or will not be permanently reinvested in the future. Our position is based upon several factors including management’s evaluation of the Company and its subsidiaries’ financial requirements, the short term and long-term operational and fiscal objectives of the Company, and the tax consequences associated with the repatriation of earnings.

Derivative Instruments

We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes.

When the underlying hedged transaction affects earnings, the gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other expense, net in our consolidated statements of (loss) income, depending on the nature of the underlying hedged transactions. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses of $1.8 million, $1.4 million, and $1.1 million in fiscal 2017, 2016 and 2015, respectively.

On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.

Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.

Stock-Based Compensation

We expense the fair value of stock-based awards granted to employees, board members and others, net of estimated forfeitures. To calculate the grant-date fair value of our stock options we use the Black-Scholes option-pricing model and for performance share units and market stock units we use Monte Carlo simulation models.

Valuation of Acquisitions

We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2017 and 2016, one one plasma collection customer accounted for 14% and 11% of our net revenues, respectively. In fiscal 2015 no customer accounted for more than 10% of our net revenues.

Certain other markets and industries can expose us to concentrations of credit risk. For example, in our Plasma business unit, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these biopharmaceutical customers can be significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Recent Accounting Pronouncements

Standards Implemented

In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. We adopted ASU No. 2014-12 in our first quarter of fiscal 2017 using the prospective method. The adoption of ASU No. 2014-12 did not have a material effect on our financial position or results of operations.

In August 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), Health and Welfare Benefit Plans (Topic 965): (Part I) Fully Benefit-Responsive Investment Contracts, (Part II) Plan Investment Disclosures, (Part III) Measurement Date Practical Expedient. Part I of ASU No. 2015-12 designates contract value as the only required measure for fully benefit-responsive investment contracts. Part II simplifies the investment disclosure requirements under Topics 820, 960, 962, and 965 for employee benefits plans and Part III provides a measurement date practical expedient for fiscal periods that do not coincide with a month-end date. ASU No. 2015-12 was effective for fiscal years beginning after December 15, 2015 with early adoption permitted. The adoption of ASU No. 2015-12 did not have a material effect on our financial position or results of operations.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance is effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. We adopted ASU No. 2014-15 in the fourth quarter of fiscal 2017. The adoption of ASU No. 2014-15 did not have a material impact our financial position or results of operations since there was no uncertainty about our ability to continue as a going concern.

In January 2017, the FASB issued ASC Update No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment. The update is effective for fiscal years beginning after December 15, 2019, including interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The purpose of Update No. 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. We early adopted ASU No. 2017-04 in fiscal 2017 on a prospective basis.

PRODUCT WARRANTIES

12 Months Ended

Apr. 01, 2017

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	April 1, 2017			April 2, 2016
Warranty accrual as of the beginning of the year	$	420		$	531
Warranty provision	400			948
Warranty spending	(644		)	(1,059		)
Warranty accrual as of the end of the year	$	176		$	420

INVENTORIES

12 Months Ended

Apr. 01, 2017

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.



(In thousands)	April 1, 2017		April 2, 2016
Raw materials	$	52,052	$	62,062
Work-in-process	10,400		13,180
Finished goods	114,477		111,786
Total Inventories	$	176,929	$	187,028

Inventories include specific charges and reserves of $11.0 million and $9.4 million for fiscal 2017 and fiscal 2016, respectively, primarily related to changes in demand for Blood Center products and the impact of the whole blood product recall in fiscal 2017.

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Apr. 01, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

Goodwill Impairment Testing and Charges

Under ASC Topic 350, Intangibles - Goodwill and Other, goodwill and intangible assets determined to have indefinite useful lives are not amortized. Instead these assets are evaluated for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. Our reporting units for purposes of assessing goodwill impairment are organized primarily based on operating segments and geography and include: (a) North America Plasma, (b) North America Blood Center, (c) North America Hospital, (d) EMEA, (e) Asia-Pacific and (f) Japan. In the prior period, North America Blood Center and North America Hospital were components of a single reporting unit, Americas Blood Center and Hospital. During the fourth quarter of fiscal 2017, we completed certain organizational changes which resulted in the disaggregation of Americas Blood Center and Hospital into two separate reporting units. The goodwill associated with the legacy Americas Blood Center and Hospital reporting unit was allocated to the North America Blood Center and North America Hospital reporting units based on their relative fair values. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit.

The results of the goodwill impairment test performed in the fourth quarter of fiscal 2017 indicated that the estimated fair value of all of our reporting units exceeded their respective carrying values, with the exception of North America Blood Center. For North America Blood Center we recorded an impairment charge of $57.0 million, which represented the entire goodwill balance associated with this reporting unit. There were no other reporting units at risk of impairment as of the fiscal 2017 annual test date.

During fiscal 2016, we recorded a goodwill impairment charge of $66.3 million associated with the EMEA reporting unit. At the time the impairment assessment was performed, this represented the entire goodwill balance of this reporting unit. During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of the Americas Blood Center and Hospital operating segment became components of the EMEA operating segment. As a result, we transferred $20.5 million of goodwill to the EMEA operating segment, which represented the portion of the goodwill associated with these components.

The changes in the carrying amount of goodwill by operating segment for fiscal 2017 and 2016 are as follows:



(In thousands)	Japan			EMEA			North America Plasma		All Other			Total
Carrying amount as of March 28, 2015	$	24,899		$	72,695		$	26,415	$	210,301		$	334,310
Impairment charge	—			(66,305		)	—		—			(66,305		)
Transfer of goodwill between segments	—			(6,390		)	—		6,390			—
Currency translation	(16		)	—			—		(149		)	(165		)
Carrying amount as of April 2, 2016	$	24,883		$	—		$	26,415	$	216,542		$	267,840
Impairment charge	—			—			—		(56,989		)	(56,989		)
Transfer of goodwill between segments	—			20,545			—		(20,545		)	—
Currency translation	(3		)	(2		)	—		(5		)	(10		)
Carrying amount as of April 1, 2017	$	24,880		$	20,543		$	26,415	$	139,003		$	210,841

Intangible Asset Impairment

During fiscal 2017, we impaired $4.8 million of intangible assets as a result of our review of non-core and underperforming assets and our decision to discontinue the use of and investment in certain assets, of which $4.0 million was included within cost of goods sold and $0.8 million was included within impairment of assets on the consolidated statements of (loss) income. These impairments impacted our All Other reportable segment.

During fiscal 2016, we recorded intangible asset impairment charges of $25.8 million, of which $6.6 million was included within cost of goods sold, while the remaining $19.2 million was included within impairment of assets on the consolidated statements of (loss) income. Of these intangible impairments, $6.6 million related to EMEA and the remaining $19.2 million related to our All Other reportable segment. These impairment charges primarily related to the SOLX technology acquired from Hemerus Medical, LLC, which resulted in impairment charges of $18.7 million and included the reversal of the $4.9 million of contingent consideration associated with the acquisition. The remaining $7.1 million of impairment charges recorded in fiscal 2016 was due to changes in the strategic direction of the Company.

The gross carrying amount of intangible assets and the related accumulated amortization as of April 1, 2017 and April 2, 2016 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net
As of April 1, 2017
Amortizable:
Patents	$	9,183	$	8,043	$	1,140
Capitalized software	49,948		21,563		28,385
Other developed technology	117,712		72,594		45,118
Customer contracts and related relationships	194,876		108,073		86,803
Trade names	7,017		5,499		1,518
Total	$	378,736	$	215,772	$	162,964
Non-amortizable:
In-process software development	$	12,743
In-process patents	1,833
Total	$	14,576



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net
As of April 2, 2016
Amortizable:
Patents	$	8,545	$	7,542	$	1,003
Capitalized software	40,488		14,791		25,697
Other developed technology	126,142		73,475		52,667
Customer contracts and related relationships	196,085		89,804		106,281
Trade names	7,083		5,204		1,879
Total	$	378,343	$	190,816	$	187,527
Non-amortizable:
In-process software development	$	14,427
In-process patents	2,504
Total	$	16,931
⁽¹⁾Includes impairment of SOLX and other intangible assets, as discussed above.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are 2 to 19 years. The changes to the net carrying value of our intangible assets from April 2, 2016 to April 1, 2017 reflect the impact of amortization expense and impairments of intangible assets, partially offset by the investment in capitalized software.

Aggregate amortization expense for amortized intangible assets for fiscal 2017 and 2016 was $37.2 million and $59.3 million, respectively, which included $4.0 million and $25.4 million, respectively, of amortization expense as a result of the intangible asset impairments discussed above. Fiscal 2015 amortization expense was $33.5 million. Future annual amortization expense on intangible assets is estimated to be as follows:



(In thousands)
Fiscal 2018	$	31,495
Fiscal 2019	$	30,089
Fiscal 2020	$	28,091
Fiscal 2021	$	26,190
Fiscal 2022	$	25,485

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS

12 Months Ended

Apr. 01, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the fiscal year ended April 1, 2017, 41.0% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of April 1, 2017 and April 2, 2016 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income (loss) until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $68.4 million as of April 1, 2017 and $107.4 million as of April 2, 2016.

During fiscal 2017, we recognized net losses of $4.6 million in earnings on our cash flow hedges, compared to recognized net gains of $8.8 million and $6.5 million during fiscal 2016 and 2015, respectively. For the fiscal year ended April 1, 2017, a $0.5 million loss, net of tax, was recorded in accumulated other comprehensive loss to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to a loss of $3.9 million, net of tax, for the fiscal year ended April 2, 2016 and a gain of $12.2 million, net of tax, for the fiscal year ended March 28, 2015. At April 1, 2017, losses of $0.5 million, net of tax, will be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of April 1, 2017 mature within twelve months.

Non-Designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $55.4 million as of April 1, 2017 and $48.8 million as of April 2, 2016.

Interest Rate Swaps

On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps") on a total notional value of $250.0 million of debt. The Swaps are amortizing and mature on August 1, 2017. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. As of April 1, 2017, the notional amount of these Swaps was $50.0 million. For fiscal 2017, 2016 and 2015, we recorded nominal activity in accumulated other comprehensive loss to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of loss and comprehensive loss for the fiscal year ended April 1, 2017.



Derivative Instruments	Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss			Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of (Loss) Income and Comprehensive Loss	Amount of Gain Excluded from Effectiveness Testing (*)		Location in Consolidated Statements of (Loss) Income and Comprehensive Loss
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	(524	)	$	(4,647	)	Net revenues, COGS, and SG&A	$	636	Other expense, net
Non-designated foreign currency hedge contracts	—			—				$	221	Other expense, net
Designated interest rate swaps, net of tax	$	160					Other expense, net	$	—
^(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of April 1, 2017 or April 2, 2016. As of April 1, 2017, we have not recognized any deferred tax assets or deferred tax liabilities for designated foreign currency hedges.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of April 1, 2017, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets:



(In thousands)	Location in Balance Sheet	April 1, 2017		April 2, 2016
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,645	$	335
Non-designated foreign currency hedge contracts	Other current assets	218		92
Designated interest rate swaps	Other current assets	64		—
		$	1,927	$	427
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	894	$	3,910
Non-designated foreign currency hedge contracts	Other current liabilities	$	72	$	146
Designated interest rate swaps	Other current liabilities	—		154
		$	966	$	4,210

Other Fair Value Measurements

ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal years ended April 1, 2017 and April 2, 2016, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following:



As of April 1, 2017	Level 1		Level 2		Total
(In thousands)
Assets
Money market funds	$	80,676	$	—	$	80,676
Designated foreign currency hedge contracts	—		1,645		1,645
Non-designated foreign currency hedge contracts	—		218		218
Designated interest rate swaps	—		64		64
	$	80,676	$	1,927	$	82,603
Liabilities
Designated foreign currency hedge contracts	$	—	$	894	$	894
Non-designated foreign currency hedge contracts	$	—	$	72	$	72
	$	—	$	966	$	966



As of April 2, 2016	Level 1		Level 2		Total
(In thousands)
Assets
Money market funds	$	72,491	$	—	$	72,491
Designated foreign currency hedge contracts	—		335		335
Non-designated foreign currency hedge contracts	—		92		92
	$	72,491	$	427	$	72,918
Liabilities
Designated foreign currency hedge contracts	$	—	$	3,910	$	3,910
Non-designated foreign currency hedge contracts	—		146		146
Designated interest rate swaps	—		154		154
	$	—	$	4,210	$	4,210

Other Fair Value Disclosures

The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value. Details pertaining to the Term Loan can be found in Note 7, Notes Payable and Long-Term Debt.

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Apr. 01, 2017

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:



(In thousands)	April 1, 2017			April 2, 2016
Term loan, net of financing fees	$	314,218		$	406,175
Bank loans and other borrowings	429			1,825
Less current portion	(61,022		)	(43,471		)
Long-term debt	$	253,625		$	364,529

On August 1, 2012, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million term loan ("Term Loan") and a $50.0 million revolving loan (“Revolving Credit Facility” and together with the Term Loan, the “Credit Facilities”). On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. The amended Credit Agreement provides for a $100.0 million Revolving Credit Facility and establishes interest rates in the range of LIBOR plus 1.125% to 1.500% depending on certain conditions. At April 1, 2017, $315.4 million was outstanding under the Term Loan with an interest rate of 2.25% and no amount was outstanding on the Revolving Credit Facility. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $315.4 million as of April 1, 2017.

Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1%. The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. The Company currently borrows in four tranches.

Interest for the Credit Facilities was based on Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of leverage ratios and customary credit terms which included financial and negative covenants. Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. The current margin of the Term Loan is 1.250% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was approximately 2.25% as of April 1, 2017. The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed.

Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0:1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0:1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities.

The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement.

Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of April 1, 2017, we were in compliance with the covenants. The goodwill and intangible asset impairment charges discussed in Note 5, Goodwill and Intangible Assets, and the property, plant and equipment impairment charges discussed in Note 12, Property Plant and Equipment, are excluded from the definition of Consolidated EBITDA in the Credit Agreement.

Commitment fee

Pursuant to the Credit Agreement, we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300%. The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.200%.

Debt issuance costs and interest

Expenses associated with the issuance of the Term Loan were capitalized and are amortized to interest expense over the life of the term loan using the effective interest method. As of April 1, 2017, the $315.4 million term loan balance was netted down by the $1.2 million of remaining debt discount, resulting in a net note payable of $314.2 million.

Interest expense was $7.9 million and $8.5 million for fiscal years ended April 1, 2017 and April 2, 2016, respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying consolidated balance sheets. As of both April 1, 2017 and April 2, 2016, we had an insignificant amount of accrued interest associated with our outstanding debt.

Maturity Profile

The maturity profile of all gross long-term debt, exclusive of debt discounts, as of April 1, 2017 is presented below:



Fiscal year (in thousands)	Credit Facilities		Bank loans and other borrowings		Total
2018	$	61,654	$	156	$	61,810
2019	194,445		138		194,583
2020	59,282		100		59,382
2021	—		28		28
2022	—		2		2
Thereafter	—		5		5
	$	315,381	$	429	$	315,810

INCOME TAXES

12 Months Ended

Apr. 01, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	2017			2016			2015
Domestic	$	(44,724	)	$	(18,526	)	$	(17,265	)
Foreign	17,248			(34,890		)	48,430
Total	$	(27,476	)	$	(53,416	)	$	31,165

The income tax provision from continuing operations contains the following components:



(In thousands)	2017			2016			2015
Current
Federal	$	(1,424	)	$	12		$	3,526
State	436			(660		)	898
Foreign	6,580			3,842			5,614
Total current	$	5,592		$	3,194		$	10,038
Deferred
Federal	(8,711		)	3,532			1,227
State	(953		)	319			3,215
Foreign	2,864			(4,882		)	(212		)
Total deferred	$	(6,800	)	$	(1,031	)	$	4,230
Total	$	(1,208	)	$	2,163		$	14,268

Our subsidiary in Puerto Rico has been granted a fifteen year tax grant which expires in calendar 2027. Our qualification for the tax grant is dependent on the continuation of our manufacturing activities in Puerto Rico. We benefit from a reduced tax rate on our earnings in Puerto Rico under the tax grant.

Our subsidiary in Switzerland operates as a principal company for direct federal tax purposes. Operating under this structure affords our Swiss subsidiary a reduced tax rate in Switzerland. Our Swiss subsidiary also operates under a 10 year tax holiday set to expire in fiscal 2018.

Our subsidiary in Malaysia has been granted a full income tax exemption to manufacture whole blood and apheresis devices that could be in effect for up to ten years, provided certain conditions are satisfied. The income tax exemption was in effect beginning June 1, 2016.

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	April 1, 2017			April 2, 2016
Deferred tax assets:
Depreciation	$	934		$	1,749
Amortization of intangibles	1,150			4,417
Inventory	7,419			7,607
Hedging	—			382
Accruals, reserves and other deferred tax assets	13,907			12,590
Net operating loss carry-forward	11,742			13,484
Stock based compensation	6,014			9,622
Tax credit carry-forward, net	17,852			16,191
Gross deferred tax assets	59,018			66,042
Less valuation allowance	(25,872		)	(24,297		)
Total deferred tax assets (after valuation allowance)	33,146			41,745
Deferred tax liabilities:
Depreciation	(30,422		)	(28,972		)
Amortization of goodwill and intangibles	(7,732		)	(23,626		)
Unremitted earnings	(1,065		)	(700		)
Other deferred tax liabilities	(2,053		)	(2,769		)
Total deferred tax liabilities	(41,272		)	(56,067		)
Net deferred tax liabilities	$	(8,126	)	$	(14,322	)

The valuation allowance increased by $1.6 million during fiscal 2017, primarily as the result of discrete valuation allowance establishments in several of our foreign subsidiaries, current year income and loss and tax credits generated in domestic and foreign jurisdictions in which we have concluded that our deferred tax assets are not more-likely-than-not realizable and the impact of foreign exchange. In determining the need for a valuation allowance, we have given consideration for our worldwide cumulative loss position, resulting from significant impairment and restructuring charges incurred in fiscal 2017 and 2016, when assessing the weight of the sources of taxable income that can be used to support the realizability of our deferred tax assets. We have assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. We have also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets. We believe we are able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence. The worldwide net deferred tax liability as of April 1, 2017 includes deferred tax liabilities related to amortizable tax basis in goodwill, which are indefinite lived and are not considered to be a source of taxable income.

As of April 1, 2017, we maintain a valuation allowance against our U.S. net deferred tax assets that are not more-likely-than-not realizable and a full valuation allowance against the net deferred tax assets of certain foreign subsidiaries.

As of April 1, 2017, we have U.S. federal net operating loss carry-forwards of approximately $23.3 million, U.S. state net operating loss carry-forwards of $33 million, federal tax credit carry-forwards of $15.1 million and state tax credit carry-forwards of $4.2 million that are available to reduce future taxable income. A portion of the federal net operating losses are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 382. Certain of the aforementioned amounts have not been recognized because they relate to excess stock based compensation. At April 1, 2017, $4.0 million of the federal net operating loss carry-forwards, $5.2 million of the state net operating loss carry-forwards, none of the federal tax credit carry-forwards and none of the state tax credit carry-forwards relate to excess stock based compensation tax deductions. We will record these off balance sheet net operating losses as a deferred tax asset, offset with an increase in the valuation allowance upon the adoption of ASU 2016-09. The federal and state net operating losses begin to expire in fiscal 2022 and 2019, respectively. The federal and state tax credits begin to expire in fiscal 2024 and 2025, respectively.

Our net operating loss and tax credit carry-forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent as defined under Section 382 and 383 of the U.S. Internal Revenue Code of 1986, respectively, as well as similar state provisions. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carry-forward to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.

As of April 1, 2017, we have foreign net operating losses of approximately $19.2 million that are available to reduce future income having unlimited carry-forward.

As of April 1, 2017, we have provided $1.1 million of U.S. deferred taxes on approximately $8.4 million of unremitted earnings which are not indefinitely reinvested. Of this amount, $0.1 million affected the Company's effective tax rate in fiscal 2017. We have not provided U.S. deferred income taxes or foreign withholding taxes on unremitted earnings of foreign subsidiaries of approximately $233.0 million as such amounts are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as our subsidiaries continue to expand their operations, to service existing debt obligations and to fund future foreign acquisitions. We do not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations.

The income tax provision from continuing operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following:



(In thousands)	2017					2016					2015
Tax at federal statutory rate	$	(9,616	)	35.0	%	$	(18,695	)	35.0	%	$	10,907		35.0	%
Difference between U.S. and foreign tax	137			(0.5	)%	10,645			(19.9	)%	(6,929		)	(22.2	)%
State income taxes net of federal benefit	(495		)	1.8	%	134			(0.3	)%	(818		)	(2.6	)%
Change in uncertain tax positions	862			(3.1	)%	(1,820		)	3.4	%	(1,762		)	(5.7	)%
Unremitted earnings	330			(1.2	)%	735			(1.4	)%	—			—	%
Deferred statutory rate changes	(383		)	1.4	%	(2,653		)	5.0	%	—			—	%
Non-deductible goodwill impairment	3,703			(13.5	)%	2,861			(5.4	)%	—			—	%
Non-deductible expenses	896			(3.2	)%	1,491			(2.8	)%	1,237			4.0	%
Research credits	(561		)	2.0	%	(672		)	1.3	%	(1,000		)	(3.2	)%
Tax amortization of goodwill	(10,564		)	38.4	%	4,185			(7.8	)%	3,826			12.3	%
Valuation allowance	13,505			(49.2	)%	5,194			(9.7	)%	8,524			27.4	%
Other, net	978			(3.5	)%	758			(1.4	)%	283			0.8	%
Income tax (benefit) provision	$	(1,208	)	4.4	%	$	2,163		(4.0	)%	$	14,268		45.8	%

We recorded an income tax benefit of $1.2 million, representing an effective tax rate of 4.4%. The effective tax rate differs from the U.S. statutory rate of 35.0% primarily as a result of the jurisdictional mix of earnings and losses generated in the U.S. and certain foreign subsidiaries that have a valuation allowance and therefore cannot be benefited. Other significant items impacting the rate include the tax provision related to the amortization of U.S. goodwill for tax purposes which gives rise to an indefinite lived deferred tax liability and the current year goodwill impairments. We have recorded a $0.1 million tax provision associated with the portion of unremitted foreign earnings that are not considered indefinitely reinvested.

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of April 1, 2017, we had $3.4 million of unrecognized tax benefits, of which $1.5 million would impact the effective tax rate, if recognized. As of April 2, 2016, we had $2.5 million of unrecognized tax benefits, of which $0.6 million would impact the effective tax rate, if recognized. At March 28, 2015, we had $7.1 million of unrecognized tax benefits, all of which $2.0 million would impact the effective tax rate, if recognized.

During the fiscal year ended April 1, 2017 our unrecognized tax benefits were increased by $0.8 million. An increase of $1.3 million in our uncertain tax positions was triggered by a reduction in workforce which impacts a previously negotiated tax holiday that requires us to maintain certain levels of headcount for a multi-year period. The establishment of this tax reserve is offset by the release of other reserves as a result of the closure of tax statutes of limitations.

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended April 1, 2017, April 2, 2016 and March 28, 2015:



(In thousands)	April 1, 2017			April 2, 2016			March 28, 2015
Beginning Balance	$	2,523		$	7,070		$	5,604
Additions for tax positions of prior years	1,279			340			3,234
Reductions of tax positions	(29		)	(4,158		)	—
Settlements with taxing authorities	—			—			(338		)
Closure of statute of limitations	(403		)	(729		)	(1,430		)
Ending Balance	$	3,370		$	2,523		$	7,070

As of April 1, 2017 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $1.5 million in the next twelve months, as a result of closure of various statutes of limitations and potential settlements with tax authorities.

Our historic practice has been and continues to be to recognize interest and penalties related to federal, state and foreign income tax matters in income tax expense. Approximately $0.2 million and $0.4 million of gross interest and penalties were accrued at April 1, 2017 and April 2, 2016, respectively, and is not included in the amounts above. There was a benefit included in tax expense associated with accrued interest and penalties of $0.2 million, $0.3 million and $0.3 million for the periods ended April 1, 2017, April 2, 2016 and March 28, 2015, respectively.

We conduct business globally and, as a result, file consolidated and separate federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions, we are no longer subject to U.S. federal, state, or local income tax examinations for years before fiscal 2014 and foreign income tax examinations for years before fiscal 2012. To the extent that we have tax attribute carry-forwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state, or foreign tax authorities to the extent utilized in a future period.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Apr. 01, 2017

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2028. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.

Approximate future basic rental commitments under operating leases as of April 1, 2017 are as follows:



Fiscal Year
(In thousands)
2018	$	4,298
2019	2,966
2020	1,906
2021	1,722
2022	1,623
Thereafter	7,031
	$	19,546

Rent expense in fiscal 2017, 2016, and 2015 was $6.2 million, $6.8 million and $6.3 million, respectively. Some of the Company's operating leases include renewal provisions, escalation clauses and options to purchase the facilities that we lease.

We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.

Italian Employment Litigation

Our Italian manufacturing subsidiary is party to several actions initiated by former employees of our facility in Ascoli-Piceno, Italy. We ceased operations at the facility in fiscal 2014 and sold the property in fiscal 2017. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) rights to payment of the extra time used for changing into and out of their working clothes at the beginning and end of each shift.

In addition, a union represented in the Ascoli plant filed an action alleging that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings.

Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment.

As of April 1, 2017, the total amount of damages claimed by the plaintiffs in these matters is approximately $4.4 million. At this point in the proceedings, we believe the losses are unlikely and therefore no amounts have been accrued. In the future, we may receive adverse rulings from the courts which could change our judgment on these cases.

SOLX Arbitration

In July 2016, H2 Equity, LLC, formerly known as Hemerus Corporation, filed an arbitration claim for $17 million in milestone and royalty payments allegedly owed as part of our acquisition of the filter and storage solution business from Hemerus Medical, LLC ("Hemerus") in fiscal 2014. The acquired storage solution is referred to as SOLX.

At the closing in April 2013, Haemonetics paid Hemerus a total of $24 million and agreed to a $3 million milestone payment due when the U.S. Food and Drug Administration ("FDA") approved a new indication for SOLX (the “24-Hour Approval”) using a filter acquired from Hemerus. We also agreed to make future royalty payments up to a cumulative maximum of $14 million based on the sale of products incorporating SOLX over a ten year period.

Due to performance issues with the Hemerus filter, Haemonetics filed for, and received, the 24-Hour Approval using a Haemonetics filter. Accordingly, Haemonetics did not pay Hemerus the $3 million milestone payment because the 24-Hour Approval was obtained using a Haemonetics filter, not a Hemerus filter. In addition, we have not paid any royalties to date as we have not made any sales of products incorporating SOLX.

H2 Equity claims, in part, that we owe them $3 million for the receipt of the 24-Hour Approval despite the use of a Haemonetics filter to obtain the approval and that we have failed to make commercially reasonable efforts to market and sell products incorporating SOLX. We believe that we have meritorious defenses to these claims.

It is not possible to accurately evaluate the likelihood or amount of any potential losses related to this claim and therefore no amounts have been accrued.

Product Recall

In June 2016, we issued a voluntary recall of certain whole blood collection kits sold to our Blood Center customers in the U.S. The recall resulted from some collection sets' filters failing to adequately remove leukocytes from collected blood. As a result of the recall, our blood center customers may have conducted further tests to confirm the blood was adequately leukoreduced, sold the blood labeled as non-leukoreduced at a lower price or discarded the blood collected using the defective sets. As a result of the recall, we have recorded total charges of $7.1 million during fiscal 2017, which consists of $3.7 million of charges associated with customer returns and inventory reserves and $3.4 million of charges associated with customer claims, as discussed below. We may record incremental charges in future periods.

We determined that the affected sets were distributed between April and June 2016. Credits have been issued to customers who returned affected sets purchased during this period. During fiscal 2017, we recorded charges of $3.7 million, which consisted of $2.5 million of sales returns, $1.1 million of net inventory reserves for the affected collection sets on-hand that had not yet been shipped to customers and $0.1 million of freight expenses.

The $3.4 million of charges associated with customer claims are based on claims seeking reimbursement for $14.2 million in losses sustained as a result of the recall. We believe it is probable that we will incur expenses as a result of these claims and that our range of loss is $3.4 million to $14.2 million, however, we do not have sufficient information to develop a best estimate within this range. Accordingly, we have recorded a liability of $3.4 million, which represents the low end of the range. While the customers making these claims purchased substantially all the affected units, incremental charges may be recorded in future periods as additional customer returns and claims data becomes available. We have an enforceable insurance policy in place which we believe provides coverage for a portion of the claims received to date. Accordingly, as of April 1, 2017, we had an insurance receivable of $2.9 million. We will assess the potential for additional insurance recoveries as we receive more information about customer claims in future reporting periods.

CAPITAL STOCK

12 Months Ended

Apr. 01, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

CAPITAL STOCK

Stock Plans

The 2005 Long-Term Incentive Compensation Plan (the “2005 Incentive Compensation Plan”) permits the award of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors.

The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 19,824,920. The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000. Any shares that are subject to the award of stock options shall be counted against this limit as one share for every one share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.02 shares for every one share granted. The total shares available for future grant as of April 1, 2017 were 5,045,728.

Stock-Based Compensation

Compensation cost related to stock-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of stock-based compensation expense, which is recorded on a straight line basis, was as follows:



(In thousands)	2017	2016	2015
Selling, general and administrative expenses	$6,894	$5,183	$11,251
Research and development	1,549	1,060	1,706
Cost of goods sold	707	706	1,138
	$9,150	$6,949	$14,095

We did not recognize an income tax benefit associated with our stock-based compensation arrangements for the fiscal years ended April 1, 2017 and April 2, 2016. We recognized an income tax benefit associated with our stock-based compensation arrangements of $4.5 million for the fiscal year ended March 28, 2015. There was no excess cash tax benefit classified as a financing cash inflow in fiscal 2017 and 2016. The excess cash tax benefit classified as a financing cash inflow in fiscal 2015 was $1.6 million.

Stock Options

Options are granted to purchase ordinary shares at prices as determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options generally vest in equal installments over a four year period for employees and one year from grant for non-employee directors. Options expire not more than 7 years from the date of the grant. The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience.

A summary of stock option activity for the fiscal year ended April 1, 2017 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at April 2, 2016	2,951,183		$	33.59	3.34	$	9,684
Granted	501,127		32.47
Exercised	(1,083,824	)	28.79
Forfeited/Canceled	(329,691	)	35.95
Outstanding at April 1, 2017	2,038,795		$	35.51	3.88	$	10,963

Exercisable at April 1, 2017	1,284,592		$	37.04	2.66	$	5,129

Vested or expected to vest at April 1, 2017	1,906,548		$	35.69	4.24	$	9,937

The total intrinsic value of options exercised was $8.3 million, $4.5 million, and $5.6 million during fiscal 2017, 2016, and 2015, respectively.

As of April 1, 2017, there was $4.9 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 3.09 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock over the expected term of the option. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period.

The assumptions utilized for option grants during the periods presented are as follows:



	2017			2016			2015
Volatility	24.0		%	22.8		%	22.5		%
Expected life (years)	4.9			4.9			4.9
Risk-free interest rate	1.2		%	1.4		%	1.5		%
Dividend yield	0.0		%	0.0		%	0.0		%
Fair value per option	$	7.61		$	7.40		$	7.91

Restricted Stock Units

Restricted Stock Units ("RSUs") generally vest in equal installments over a four year period for employees and one year from grant for non-employee directors. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

A summary of RSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	380,871		$	34.33
Granted	212,105		32.61
Vested	(150,113	)	34.98
Forfeited	(101,222	)	33.70
Unvested at April 1, 2017	341,641		$	33.16

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows:



(In thousands, except per share data)	2017		2016		2015
Grant-date fair value per RSU	$	32.61	$	33.19	$	34.89
Fair value of RSUs vested	$	34.98	$	36.07	$	36.62

As of April 1, 2017, there was $8.4 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.87 years.

Performance Stock Units

The grant date fair value of Performance Stock Units ("PSUs"), adjusted for estimated forfeitures, is recognized as expense on a straight line basis from the grant date through the end of the performance period. The value of these PSUs is based on relative shareholder return which equals total shareholder return for the Company as compared to total shareholder return of the PSU comparison group, measured over a three year performance period. Depending on the Company's relative performance during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted. As a result, we may issue up to 569,250 shares related to these awards. If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100% of the target award, regardless of the Company's performance relative to the Company's comparison group.

PSUs granted in fiscal 2016 and 2015 have a comparison group consisting of the Standard and Poor's ("S&P") Health Care Equipment Index, while PSUs granted in fiscal 2017 have a comparison group consisting of the S&P Small Cap 600 and the S&P Mid Cap 400 indices.

In addition to these relative shareholder return PSUs, the Company's Chief Executive Officer, upon hire, received a PSU grant with performance conditions based on the financial results of the Company and other internal metrics.

A summary of PSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	102,336		$	31.38
Granted	228,884		34.07
Vested	—		—
Forfeited	(46,595	)	30.68
Unvested at April 1, 2017	284,625		$	33.66

The Company uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards with market conditions. The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows:



	2017		2016		2015
Expected stock price volatility	26.39	%	22.27	%	20.08	%
Peer group stock price volatility	33.86	%	31.95	%	31.52	%
Correlation of returns	51.17	%	26.27	%	30.52	%

The weighted-average grant-date fair value of PSUs granted was $34.07, $29.20 and $35.09 in fiscal 2017, 2016, and 2015 respectively.

As of April 1, 2017, there was $7.8 million of total unrecognized compensation cost related to non-vested performance share units. This cost is expected to be recognized over a weighted average period of 2.29 years.

Market Stock Units

The Company used the Monte Carlo model to determine the fair value of each market stock unit granted in fiscal 2016 and 2015. The grant date fair value of Market Stock Units ("MSUs"), adjusted for estimated forfeitures, was recognized as expense on a straight line basis from the grant date through the end of the performance period. The value of these MSUs was based the performance of Haemonetics’ stock through March 31, 2017. Because Haemonetics' stock was below the minimum threshold price of $50 per share during the relevant measurement period, the holders received no market share units upon vesting. There were no MSUs granted in fiscal 2017.

A summary of MSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	152,968		$	24.84
Granted	—		—
Vested	(116,550	)	—
Forfeited	(36,418	)	13.42
Unvested at April 1, 2017	—		$	—

Employee Stock Purchase Plan

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 3,200,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% or more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	2017		2016		2015
Volatility	31.3	%	21.1	%	23.7	%
Expected life (months)	6		6		6
Risk-free interest rate	—	%	0.2	%	0.1	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $7.79, $7.80, and $7.09 during fiscal 2017, 2016, and 2015, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

EARNINGS PER SHARE ("EPS")

12 Months Ended

Apr. 01, 2017

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



(In thousands, except per share amounts)	2017			2016			2015
Basic EPS
Net (loss) income	$	(26,268	)	$	(55,579	)	$	16,897
Weighted average shares	51,524			50,910			51,533
Basic (loss) income per share	$	(0.51	)	$	(1.09	)	$	0.33
Diluted EPS
Net (loss) income	$	(26,268	)	$	(55,579	)	$	16,897
Basic weighted average shares	51,524			50,910			51,533
Net effect of common stock equivalents	—			—			556
Diluted weighted average shares	51,524			50,910			52,089
Diluted (loss) income per share	$	(0.51	)	$	(1.09	)	$	0.32

Basic earnings per share is calculated using our weighted-average outstanding common shares. Diluted earnings per share is calculated using our weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For fiscal 2017 and 2016, we recognized a net loss; therefore we excluded the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect. Fiscal 2015 weighted average shares outstanding, assuming dilution, excludes the impact of 1.6 million stock options and restricted share units because either the effect would have been anti-dilutive or the performance criteria related to the units had not yet been met.

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Apr. 01, 2017

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

Property and equipment consisted of the following:



(In thousands)	April 1, 2017			April 2, 2016
Land	$	7,389		$	7,905
Building and building improvements	109,933			117,132
Plant equipment and machinery	253,693			238,549
Office equipment and information technology	129,753			127,019
Haemonetics equipment	306,714			295,853
Total	807,482			786,458
Less: accumulated depreciation and amortization	(483,620		)	(448,824		)
Property, plant and equipment, net	$	323,862		$	337,634

During fiscal 2017, we impaired $13.3 million of property, plant and equipment as a result of our review of non-core and underperforming assets and our decision to discontinue the use of and investment in certain assets, of which $0.8 million was included within impairment of assets on the consolidated statements of (loss) income and the remaining $12.5 million was included within cost of goods sold. These impairments impacted Americas Blood Center and Hospital, North America Plasma and EMEA segments by $10.6 million, $1.7 million and $1.0 million, respectively.

During fiscal 2016, we impaired $9.1 million of property, plant and equipment as a result of our global strategic review, of which $6.9 million was included within impairment of assets on the consolidated statements of (loss) income and the remaining $2.2 million was included within cost of goods sold. These impairments impacted our Americas Blood Center and Hospital and EMEA segments by $3.0 million and $6.1 million, respectively.

Depreciation expense was $66.5 million and $56.8 million in fiscal 2017 and fiscal 2016, respectively, which includes $10.0 million and $0.8 million, respectively, of additional depreciation expense due to asset impairments. Depreciation expense was $52.6 million for fiscal 2015.

RETIREMENT PLANS

12 Months Ended

Apr. 01, 2017

Compensation and Retirement Disclosure [Abstract]

RETIREMENT PLANS

Defined Contribution Plans

We have a Savings Plus Plan (the "Plan") that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $5.1 million, $5.4 million, and $5.8 million in fiscal 2017, 2016, and 2015, respectively. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Plan in fiscal 2017, 2016, or 2015.

Some of our subsidiaries also have defined contribution plans, to which both the employee and the employer make contributions. The employer contributions to these plans totaled $0.8 million in both fiscal 2017 and 2016 and $1.0 million in fiscal 2015.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive loss on its consolidated statement of stockholders’ equity and consolidated statement of comprehensive income (loss).

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change.

Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:



(In thousands)	2017			2016			2015
Service cost	$	3,404		$	3,560		$	2,979
Interest cost on benefit obligation	287			371			686
Expected return on plan assets	(308		)	(330		)	(449		)
Actuarial loss	532			598			107
Amortization of unrecognized prior service cost	(119		)	(38		)	(29		)
Amortization of unrecognized transition obligation	37			42			45
Settlement loss recognized	289			—			—
Totals	$	4,122		$	4,203		$	3,339

The activity under those defined benefit plans are as follows:



(In thousands)	April 1, 2017			April 2, 2016
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(37,919	)	$	(40,567	)
Service cost	(3,404		)	(3,560		)
Interest cost	(287		)	(371		)
Benefits paid	1,291			3,780
Actuarial gain	4,615			424
Employee and plan participants contribution	(2,463		)	(1,839		)
Plan amendments	—			833
Plan settlements	6,960			—
Foreign currency changes	(138		)	3,381
Benefit obligation, end of year	$	(31,345	)	$	(37,919	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	19,852		$	23,165
Company contributions	1,788			1,987
Benefits paid	(1,192		)	(3,779		)
Gain on plan assets	414			446
Employee and plan participants contributions	2,424			1,861
Plan settlements	(6,850		)	—
Foreign currency changes	849			(3,828		)
Fair value of Plan Assets, end of year	$	17,285		$	19,852
Funded Status^*	$	(14,060	)	$	(18,067	)
Unrecognized net actuarial loss	4,319			10,168
Unrecognized initial obligation	—			37
Unrecognized prior service cost	(1,019		)	(1,186		)
Net amount recognized	$	(10,760	)	$	(9,048	)
^* The unfunded status is all non-current

One of the benefit plans is funded by benefit payments made by the Company through the purchase of reinsurance contracts which do not qualify as plan assets under ASC Topic 715. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $8.8 million and $8.7 million as of April 1, 2017 and April 2, 2016, respectively, and the total asset value associated with the reinsurance contracts was $5.4 million as of both April 1, 2017 and April 2, 2016.

The accumulated benefit obligation for all plans was $28.7 million and $36.4 million for the fiscal year ended April 1, 2017 and April 2, 2016, respectively. There were no plans where the plan assets were greater than the accumulated benefit obligation as of April 1, 2017 and April 2, 2016.

The components of the change recorded in our accumulated other comprehensive loss related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, March 29, 2014	$	(4,592	)
Obligation at transition	(19		)
Actuarial loss	(6,198		)
Prior service cost	1,886
Balance as of March 28, 2015	$	(8,923	)
Obligation at transition	33
Actuarial loss	681
Prior service cost	717
Balance as of April 2, 2016	$	(7,492	)
Obligation at transition	32
Actuarial loss	5,126
Prior service cost	63
Balance as of April 1, 2017	$	(2,271	)

We expect to amortize $0.2 million from accumulated other comprehensive loss to net periodic benefit cost during fiscal 2018.

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	2017		2016		2015
Discount rate	0.76	%	0.72	%	0.93	%
Rate of increased salary levels	1.43	%	1.58	%	1.65	%
Expected long-term rate of return on assets	1.10	%	1.20	%	1.68	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.

We have no other material obligation for post-retirement or post-employment benefits.

Our investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of April 1, 2017. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 6, Derivatives and Fair Value Measurements, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at April 1, 2017. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments are as follows:



(in thousands)
Fiscal 2018	$	1,396
Fiscal 2019	1,451
Fiscal 2020	1,394
Fiscal 2021	1,411
Fiscal 2022	1,617
Fiscal 2023-2027	6,869
	$	14,138

The Company's contributions for fiscal 2018 are expected to be consistent with the current year.

SEGMENT AND ENTERPRISE-WIDE INFORMATION

12 Months Ended

Apr. 01, 2017

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:


•	Japan


•	EMEA


•	North America Plasma


•	All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of All Other are now reported as components of EMEA. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2017. These changes did not have an impact on our ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year, therefore segment information is presented on this basis.

Selected information by business segment is presented below:



(In thousands)	2017			2016			2015
Net revenues
Japan	$	74,695		$	84,270		$	83,547
EMEA	198,396			204,192			219,153
North America Plasma	309,718			279,803			240,705
All Other	316,771			342,249			340,427
Net revenues before foreign exchange impact	899,580			910,515			883,832
Effect of exchange rates	(13,464		)	(1,683		)	26,541
Net revenues	$	886,116		$	908,832		$	910,373



(In thousands)	2017			2016			2015
Segment operating income
Japan	$	32,906		$	38,280		$	36,843
EMEA	49,105			47,168			60,101
North America Plasma	105,253			109,220			89,092
All Other	109,296			120,562			131,471
Segment operating income	296,560			315,230			317,507
Corporate operating expenses	176,372			199,072			193,910
Effect of exchange rates	(4,772		)	3,546			13,906
Restructuring and turnaround costs	34,337			42,185			69,697
Deal amortization	27,107			28,958			30,184
Impairment of assets	73,353			97,230			—
Contingent consideration income	—			(4,727		)	(2,918		)
Operating (loss) income	$	(19,381	)	$	(43,942	)	$	40,540



(In thousands)	2017		2016		2015
Depreciation and amortization
Japan	$	827	$	774	$	767
EMEA	4,255		5,146		5,045
North America Plasma	13,022		12,944		11,229
All Other	71,629		71,047		69,012
Total depreciation and amortization (excluding impairment charges)	$	89,733	$	89,911	$	86,053



(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
Long-lived assets⁽¹⁾
Japan	$	21,412	$	33,159	$	31,810
EMEA	63,854		63,861		66,223
North America Plasma	142,164		116,001		101,272
All Other	96,432		124,613		122,643
Total long-lived assets	$	323,862	$	337,634	$	321,948
⁽¹⁾Long-lived assets are comprised of property, plant and equipment.

Long-lived assets in our principle operating regions are as follows:



(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
United States	$	241,610	$	231,744	$	208,439
Japan	1,691		2,022		1,618
Europe	12,952		18,672		27,786
Asia	34,174		40,235		39,032
Other	33,435		44,961		45,073
Total	$	323,862	$	337,634	$	321,948

In fiscal 2017, we organized our current products into four business units for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units, however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:



(In thousands)	2017		2016		2015
Plasma	410,727		381,776		352,911
Blood Center	303,890		355,108		386,147
Cell Processing	105,376		112,483		120,434
Hemostasis Management	66,123		59,465		50,881
Net revenues	$	886,116	$	908,832	$	910,373

Net revenues generated in our principle operating regions are as follows:



(In thousands)	2017		2016		2015
United States	$	522,686	$	519,440	$	494,788
Japan	79,266		81,411		88,298
Europe	166,007		187,725		215,575
Asia	109,858		111,758		102,095
Other	8,299		8,498		9,617
Total	$	886,116	$	908,832	$	910,373

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

RESTRUCTURING

12 Months Ended

Apr. 01, 2017

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.

During fiscal 2017, we launched a multi-year restructuring initiative designed to reposition our organization and improve our cost structure. This initiative includes a reduction of headcount and operating costs, simplification of certain product lines, and modification of manufacturing operations to align with our strategic direction.

The fiscal 2017 phase was expected to incur approximately $26 million of restructuring and turnaround charges and was estimated to achieve cost savings of $40 million. During fiscal 2017, we incurred $28.7 million of restructuring and turnaround charges under this initiative and exceeded our estimated savings target of $40 million. As of April 1, 2017, this initial phase was substantially complete. Additionally, during fiscal 2017 and fiscal 2016, we recorded $5.6 million and $42.3 million, respectively, of restructuring and turnaround charges under a prior program. We continue to assess non-core and underperforming assets and evaluate opportunities to improve our cost structure as part of our turnaround and expect to incur additional charges and benefits during fiscal 2018 and beyond.

The following summarizes the restructuring activity for the fiscal year ended April 1, 2017, April 2, 2016, and March 28, 2015, respectively:



(In thousands)	Severance and Other Employee Costs			Other Costs			Accelerated Depreciation			Asset Write Down			Total Restructuring
Balance at March 29, 2014	$	22,908		$	728		$	—		$	—		$	23,636
Costs incurred	19,879			15,362			1,326			296			36,863
Payments	(26,394		)	(15,871		)	—			—			(42,265		)
Non-cash adjustments	—			—			(1,326		)	(296		)	(1,622		)
Balance at March 28, 2015	$	16,393		$	219		$	—		$	—		$	16,612
Costs incurred	10,707			7,846			1,469			3,033			23,055
Payments	(18,348		)	(8,065		)	—			—			(26,413		)
Non-cash adjustments	—			—			(1,469		)	(3,033		)	(4,502		)
Balance at April 2, 2016	$	8,752		$	—		$	—		$	—		$	8,752
Costs incurred	19,521			1,512			—			800			21,833
Payments	(20,866		)	(1,451		)	—			—			(22,317		)
Non-cash adjustments	—			—			—			(800		)	(800		)
Balance at April 1, 2017	$	7,407		$	61		$	—		$	—		$	7,468

The substantial majority of restructuring expenses have been included as a component of selling, general and administrative expense in the accompanying consolidated statements of (loss) income. As of April 1, 2017, we had a restructuring liability of $7.5 million, of which, approximately $7.1 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, we also incurred $12.5 million, $19.2 million and $32.8 million in fiscal 2017, 2016 and 2015, respectively, of costs that do not constitute as restructuring under ASC 420, which we refer to as "Turnaround Costs". These costs consist primarily of expenditures directly related to our restructuring initiative and include program management, implementation of the global strategic review initiatives and accelerated depreciation.

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs
(in thousands)	2017		2016		2015
Japan	$	819	$	9	$	258
EMEA	4,272		3,210		3,310
North America Plasma	366		—		360
All Other	16,376		19,836		32,935
Total	$	21,833	$	23,055	$	36,863

Turnaround costs
(in thousands)	2017		2016		2015
Japan	$	2	$	416	$	158
EMEA	94		961		838
North America Plasma	972		—		28
All Other	11,415		17,852		31,810
Total	$	12,483	$	19,229	$	32,834

Total restructuring and turnaround	$	34,316	$	42,284	$	69,697

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Apr. 01, 2017
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other. Pursuant to ASC Topic 350, we capitalize costs incurred during the application development stage of software developed for internal use, and expense costs incurred during the preliminary project and the post-implementation operation stages of development. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. For costs incurred related to the development of software to be sold, leased, or otherwise marketed, we apply the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $11.0 million and $17.0 million in software development costs for ongoing initiatives during the fiscal years ended April 1, 2017 and April 2, 2016, respectively. At April 1, 2017 and April 2, 2016, we have a total of $62.7 million and $54.9 million of software costs capitalized, of which $12.7 million and $14.4 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. In connection with these development activities, we capitalized interest of $0.3 million and $0.2 million in fiscal 2017 and 2016, respectively. We amortize capitalized costs when the products are released for sale. During fiscal 2017, $9.5 million of capitalized costs were placed into service, compared to $8.7 million of capitalized costs placed into service during fiscal 2016. Amortization of capitalized software development cost expense was $9.7 million, $10.9 million and $3.2 million for fiscal 2017, 2016 and 2015, respectively. Amortization expense in fiscal 2017 and 2016 includes $4.0 million and $6.0 million of impairment charges. These impairment charges are classified within costs of goods sold on our consolidated statements of (loss) income and relate to capitalized software projects included in our All Other segment.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

SUMMARY OF QUARTERLY DATA (UNAUDITED)

12 Months Ended

Apr. 01, 2017

Quarterly Financial Data [Abstract]

SUMMARY OF QUARTERLY DATA (UNAUDITED)



(In thousands)	Three months ended
Fiscal 2017	July 2, 2016			October 1, 2016		December 31, 2016			April 1, 2017
Net revenues	$	209,956		$	220,253	$	227,841		$	228,066
Gross profit	$	91,056		$	104,248	$	101,079		$	82,111
Operating income (loss)	$	(7,881	)	$	24,794	$	21,212		$	(57,506	)
Net (loss) income	$	(10,346	)	$	19,825	$	15,393		$	(51,140	)
Per share data:
Net (loss) income:
Basic	$	(0.20	)	$	0.39	$	0.30		$	(0.98	)
Diluted	$	(0.20	)	$	0.38	$	0.30		$	(0.98	)

(In thousands)	Three months ended
Fiscal 2016	June 27, 2015			September 26, 2015		December 26, 2015			April 2, 2016
Net revenues	$	213,413		$	219,693	$	233,384		$	242,342
Gross profit	$	102,539		$	105,297	$	108,855		$	89,223
Operating (loss) income	$	3,606		$	19,179	$	(61,177	)	$	(5,550	)
Net (loss) income	$	(267	)	$	12,863	$	(59,440	)	$	(8,735	)
Per share data:
Net (loss) income:
Basic	$	(0.01	)	$	0.25	$	(1.17	)	$	(0.17	)
Diluted	$	(0.01	)	$	0.25	$	(1.17	)	$	(0.17	)

The operating results for the second and fourth quarters of fiscal 2017 and all four quarters of fiscal 2016 include certain misstatements that were determined to be immaterial both individually and in the aggregate. The misstatement in the fourth quarter of fiscal 2017 was primarily driven by the correction of an error in capitalized manufacturing variances which resulted in an overstatement of net loss in the fourth quarter of fiscal 2017 and an overstatement of net income in the second quarter of fiscal 2017 and each quarter of fiscal 2016.

The operating results for the first quarter of fiscal 2016 also include the correction of an understatement of the provision for income taxes in fiscal 2015 and the operating results for the third quarter of fiscal 2016 also include the correction of an overstated liability in fiscal 2014.

Below is a summary of the net overstatement/(understatement) of the Company’s reported operating income and net income for the second and fourth quarters of fiscal 2017 and all four quarters of fiscal 2016 as a result of the misstatements in each reporting period. In the fourth quarter of fiscal 2017 and the first, third and fourth quarters of fiscal 2016, the Company reported an operating loss, a net loss or both. For such periods, an understatement of income means that the reported loss was too high, while an overstatement of income means that the reported loss was too low.



(In thousands)	Overstatement/(Understatement)
Three Months Ended	Operating (Loss) Income		Net (Loss) Income
April 1, 2017	(3,720	)	(4,032	)
October 1, 2016	888		1,224
April 2, 2016	(3,352	)	(2,207	)
December 26, 2015	4,776		4,584
September 26, 2015	1,193		933
June 27, 2015	1,297		219

ACCUMULATED OTHER COMPREHENSIVE LOSS

12 Months Ended

Apr. 01, 2017

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended April 1, 2017 and April 2, 2016:



(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)
Other comprehensive (loss) income before reclassifications	(1,987		)	884			(3,938		)	(5,041		)
Amounts reclassified from accumulated other comprehensive loss	—			547			(8,822		)	(8,275		)
Net current period other comprehensive (loss) income	(1,987		)	1,431			(12,760		)	(13,316		)
Balance as of April 2, 2016	$	(22,499	)	$	(7,492	)	$	(5,049	)	$	(35,040	)
Other comprehensive (loss) income before reclassifications	(7,336		)	4,851			(364		)	(2,849		)
Amounts reclassified from accumulated other comprehensive loss	—			369			4,647			5,016
Net current period other comprehensive (loss) income	(7,336		)	5,220			4,283			2,167
Balance as of April 1, 2017	$	(29,835	)	$	(2,272	)	$	(766	)	$	(32,873	)

The details about the amount reclassified from accumulated other comprehensive loss for the years ended April 1, 2017 and April 2, 2016 are as follows:



(In thousands)	Amounts Reclassified from Accumulated Other Comprehensive Loss						Affected Line in the Statement of (Loss) Income
Derivative instruments reclassified to income statement	Year ended April 1, 2017			Year ended April 2, 2016
Realized net (loss) gain on derivatives	$	(5,227	)	$	8,654		Net revenues, cost of goods sold, other expense, net
Income tax effect	580			168			Provision (benefit) for income taxes
Net of taxes	$	(4,647	)	$	8,822

Pension items reclassified to income statement
Realized net loss on pension assets	$	450		$	602		Other expense, net
Income tax effect	(81		)	(55		)	Provision (benefit) for income taxes
Net of taxes	$	369		$	547

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Apr. 01, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On April 27, 2017, we sold our SEBRA sealers product line to Machine Solutions Inc. because it was no longer aligned with our long-term strategic objectives. In connection with this transaction, we received net proceeds of $9 million. These proceeds are subject to a post-closing adjustment based on final asset values as determined during the 90 days transition period. The preliminary pre-tax gain expected to be recorded as a result of this transaction is $8 million. The SEBRA portfolio includes a suite of products which primarily include radio frequency sealers that are used to seal tubing as part of the collection of whole blood and blood components, particularly plasma.

VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Apr. 01, 2017

Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

HAEMONETICS CORPORATION

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Fiscal Year		Charged to Costs and Expenses		Write-Offs (Net of Recoveries)			Balance at End of Fiscal Year
For Year Ended April 1, 2017
Allowance for Doubtful Accounts	$	2,253	$	103	$	172		$	2,184
For Year Ended April 2, 2016
Allowance for Doubtful Accounts	$	1,749	$	728	$	(224	)	$	2,253
For Year Ended March 28, 2015
Allowance for Doubtful Accounts	$	1,676	$	399	$	(326	)	$	1,749

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Apr. 01, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Fiscal Year

Principles of Consolidation

Use of Estimates

Reclassifications

Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.

Translation of Foreign Currencies

Cash and Cash Equivalents

Allowance for Doubtful Accounts

Inventories

Property, Plant and Equipment



Asset Classification		Estimated Useful Lives
Building		30-40 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		2-10 Years
Haemonetics equipment		3-7 Years


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Goodwill and Intangible Assets

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of (loss) income.

Shipping and Handling Costs

Income Taxes

Derivative Instruments

Stock-Based Compensation

Valuation of Acquisitions

Concentration of Credit Risk and Significant Customers

Recent Accounting Pronouncements

Standards Implemented

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Apr. 01, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives



Asset Classification		Estimated Useful Lives
Building		30-40 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		2-10 Years
Haemonetics equipment		3-7 Years

Schedule of Other Accrued Liabilities

Other Current Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	April 1, 2017		April 2, 2016
VAT liabilities	$	4,051	$	1,289
Forward contracts	966		4,210
Deferred revenue	26,485		27,053
Accrued taxes	4,407		3,876
All other	27,741		30,180
Total	$	63,650	$	66,608

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	April 1, 2017		April 2, 2016
Unfunded pension liability	14,060		18,067
Unrecognized tax benefit	1,627		2,283
All other	6,494		5,756
Total	$	22,181	$	26,106

PRODUCT WARRANTIES (Tables)

12 Months Ended

Apr. 01, 2017

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	April 1, 2017			April 2, 2016
Warranty accrual as of the beginning of the year	$	420		$	531
Warranty provision	400			948
Warranty spending	(644		)	(1,059		)
Warranty accrual as of the end of the year	$	176		$	420

INVENTORIES (Tables)

12 Months Ended

Apr. 01, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.



(In thousands)	April 1, 2017		April 2, 2016
Raw materials	$	52,052	$	62,062
Work-in-process	10,400		13,180
Finished goods	114,477		111,786
Total Inventories	$	176,929	$	187,028

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Apr. 01, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill by operating segment for fiscal 2017 and 2016 are as follows:



(In thousands)	Japan			EMEA			North America Plasma		All Other			Total
Carrying amount as of March 28, 2015	$	24,899		$	72,695		$	26,415	$	210,301		$	334,310
Impairment charge	—			(66,305		)	—		—			(66,305		)
Transfer of goodwill between segments	—			(6,390		)	—		6,390			—
Currency translation	(16		)	—			—		(149		)	(165		)
Carrying amount as of April 2, 2016	$	24,883		$	—		$	26,415	$	216,542		$	267,840
Impairment charge	—			—			—		(56,989		)	(56,989		)
Transfer of goodwill between segments	—			20,545			—		(20,545		)	—
Currency translation	(3		)	(2		)	—		(5		)	(10		)
Carrying amount as of April 1, 2017	$	24,880		$	20,543		$	26,415	$	139,003		$	210,841

Schedule of Amoritized Intangibles

The gross carrying amount of intangible assets and the related accumulated amortization as of April 1, 2017 and April 2, 2016 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net
As of April 1, 2017
Amortizable:
Patents	$	9,183	$	8,043	$	1,140
Capitalized software	49,948		21,563		28,385
Other developed technology	117,712		72,594		45,118
Customer contracts and related relationships	194,876		108,073		86,803
Trade names	7,017		5,499		1,518
Total	$	378,736	$	215,772	$	162,964
Non-amortizable:
In-process software development	$	12,743
In-process patents	1,833
Total	$	14,576



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net
As of April 2, 2016
Amortizable:
Patents	$	8,545	$	7,542	$	1,003
Capitalized software	40,488		14,791		25,697
Other developed technology	126,142		73,475		52,667
Customer contracts and related relationships	196,085		89,804		106,281
Trade names	7,083		5,204		1,879
Total	$	378,343	$	190,816	$	187,527
Non-amortizable:
In-process software development	$	14,427
In-process patents	2,504
Total	$	16,931
⁽¹⁾Includes impairment of SOLX and other intangible assets, as discussed above.

Schedule of Future Amortization Expense

Future annual amortization expense on intangible assets is estimated to be as follows:



(In thousands)
Fiscal 2018	$	31,495
Fiscal 2019	$	30,089
Fiscal 2020	$	28,091
Fiscal 2021	$	26,190
Fiscal 2022	$	25,485

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Apr. 01, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



Derivative Instruments	Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss			Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of (Loss) Income and Comprehensive Loss	Amount of Gain Excluded from Effectiveness Testing (*)		Location in Consolidated Statements of (Loss) Income and Comprehensive Loss
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	(524	)	$	(4,647	)	Net revenues, COGS, and SG&A	$	636	Other expense, net
Non-designated foreign currency hedge contracts	—			—				$	221	Other expense, net
Designated interest rate swaps, net of tax	$	160					Other expense, net	$	—
^(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets:



(In thousands)	Location in Balance Sheet	April 1, 2017		April 2, 2016
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,645	$	335
Non-designated foreign currency hedge contracts	Other current assets	218		92
Designated interest rate swaps	Other current assets	64		—
		$	1,927	$	427
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	894	$	3,910
Non-designated foreign currency hedge contracts	Other current liabilities	$	72	$	146
Designated interest rate swaps	Other current liabilities	—		154
		$	966	$	4,210

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following:



As of April 1, 2017	Level 1		Level 2		Total
(In thousands)
Assets
Money market funds	$	80,676	$	—	$	80,676
Designated foreign currency hedge contracts	—		1,645		1,645
Non-designated foreign currency hedge contracts	—		218		218
Designated interest rate swaps	—		64		64
	$	80,676	$	1,927	$	82,603
Liabilities
Designated foreign currency hedge contracts	$	—	$	894	$	894
Non-designated foreign currency hedge contracts	$	—	$	72	$	72
	$	—	$	966	$	966



As of April 2, 2016	Level 1		Level 2		Total
(In thousands)
Assets
Money market funds	$	72,491	$	—	$	72,491
Designated foreign currency hedge contracts	—		335		335
Non-designated foreign currency hedge contracts	—		92		92
	$	72,491	$	427	$	72,918
Liabilities
Designated foreign currency hedge contracts	$	—	$	3,910	$	3,910
Non-designated foreign currency hedge contracts	—		146		146
Designated interest rate swaps	—		154		154
	$	—	$	4,210	$	4,210

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

12 Months Ended

Apr. 01, 2017

Debt Disclosure [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:



(In thousands)	April 1, 2017			April 2, 2016
Term loan, net of financing fees	$	314,218		$	406,175
Bank loans and other borrowings	429			1,825
Less current portion	(61,022		)	(43,471		)
Long-term debt	$	253,625		$	364,529

Schedule of Notes Payable and Long-Term Debt Maturities

The maturity profile of all gross long-term debt, exclusive of debt discounts, as of April 1, 2017 is presented below:



Fiscal year (in thousands)	Credit Facilities		Bank loans and other borrowings		Total
2018	$	61,654	$	156	$	61,810
2019	194,445		138		194,583
2020	59,282		100		59,382
2021	—		28		28
2022	—		2		2
Thereafter	—		5		5
	$	315,381	$	429	$	315,810

INCOME TAXES (Tables)

12 Months Ended

Apr. 01, 2017

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	2017			2016			2015
Domestic	$	(44,724	)	$	(18,526	)	$	(17,265	)
Foreign	17,248			(34,890		)	48,430
Total	$	(27,476	)	$	(53,416	)	$	31,165

Schedule of Income Tax Provision Components

The income tax provision from continuing operations contains the following components:



(In thousands)	2017			2016			2015
Current
Federal	$	(1,424	)	$	12		$	3,526
State	436			(660		)	898
Foreign	6,580			3,842			5,614
Total current	$	5,592		$	3,194		$	10,038
Deferred
Federal	(8,711		)	3,532			1,227
State	(953		)	319			3,215
Foreign	2,864			(4,882		)	(212		)
Total deferred	$	(6,800	)	$	(1,031	)	$	4,230
Total	$	(1,208	)	$	2,163		$	14,268

Schedule of Net Deferred Tax Asset

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	April 1, 2017			April 2, 2016
Deferred tax assets:
Depreciation	$	934		$	1,749
Amortization of intangibles	1,150			4,417
Inventory	7,419			7,607
Hedging	—			382
Accruals, reserves and other deferred tax assets	13,907			12,590
Net operating loss carry-forward	11,742			13,484
Stock based compensation	6,014			9,622
Tax credit carry-forward, net	17,852			16,191
Gross deferred tax assets	59,018			66,042
Less valuation allowance	(25,872		)	(24,297		)
Total deferred tax assets (after valuation allowance)	33,146			41,745
Deferred tax liabilities:
Depreciation	(30,422		)	(28,972		)
Amortization of goodwill and intangibles	(7,732		)	(23,626		)
Unremitted earnings	(1,065		)	(700		)
Other deferred tax liabilities	(2,053		)	(2,769		)
Total deferred tax liabilities	(41,272		)	(56,067		)
Net deferred tax liabilities	$	(8,126	)	$	(14,322	)

Schedule of Effective Income Tax Rate Reconciliation

The income tax provision from continuing operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following:



(In thousands)	2017					2016					2015
Tax at federal statutory rate	$	(9,616	)	35.0	%	$	(18,695	)	35.0	%	$	10,907		35.0	%
Difference between U.S. and foreign tax	137			(0.5	)%	10,645			(19.9	)%	(6,929		)	(22.2	)%
State income taxes net of federal benefit	(495		)	1.8	%	134			(0.3	)%	(818		)	(2.6	)%
Change in uncertain tax positions	862			(3.1	)%	(1,820		)	3.4	%	(1,762		)	(5.7	)%
Unremitted earnings	330			(1.2	)%	735			(1.4	)%	—			—	%
Deferred statutory rate changes	(383		)	1.4	%	(2,653		)	5.0	%	—			—	%
Non-deductible goodwill impairment	3,703			(13.5	)%	2,861			(5.4	)%	—			—	%
Non-deductible expenses	896			(3.2	)%	1,491			(2.8	)%	1,237			4.0	%
Research credits	(561		)	2.0	%	(672		)	1.3	%	(1,000		)	(3.2	)%
Tax amortization of goodwill	(10,564		)	38.4	%	4,185			(7.8	)%	3,826			12.3	%
Valuation allowance	13,505			(49.2	)%	5,194			(9.7	)%	8,524			27.4	%
Other, net	978			(3.5	)%	758			(1.4	)%	283			0.8	%
Income tax (benefit) provision	$	(1,208	)	4.4	%	$	2,163		(4.0	)%	$	14,268		45.8	%

Summary of Gross Unrecognized Tax Benefits

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended April 1, 2017, April 2, 2016 and March 28, 2015:



(In thousands)	April 1, 2017			April 2, 2016			March 28, 2015
Beginning Balance	$	2,523		$	7,070		$	5,604
Additions for tax positions of prior years	1,279			340			3,234
Reductions of tax positions	(29		)	(4,158		)	—
Settlements with taxing authorities	—			—			(338		)
Closure of statute of limitations	(403		)	(729		)	(1,430		)
Ending Balance	$	3,370		$	2,523		$	7,070

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Apr. 01, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Approximate Future Basic Rental Commitments under Operating Leases

Approximate future basic rental commitments under operating leases as of April 1, 2017 are as follows:



Fiscal Year
(In thousands)
2018	$	4,298
2019	2,966
2020	1,906
2021	1,722
2022	1,623
Thereafter	7,031
	$	19,546

CAPITAL STOCK (Tables)

12 Months Ended

Apr. 01, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Cost



(In thousands)	2017	2016	2015
Selling, general and administrative expenses	$6,894	$5,183	$11,251
Research and development	1,549	1,060	1,706
Cost of goods sold	707	706	1,138
	$9,150	$6,949	$14,095

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended April 1, 2017 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at April 2, 2016	2,951,183		$	33.59	3.34	$	9,684
Granted	501,127		32.47
Exercised	(1,083,824	)	28.79
Forfeited/Canceled	(329,691	)	35.95
Outstanding at April 1, 2017	2,038,795		$	35.51	3.88	$	10,963

Exercisable at April 1, 2017	1,284,592		$	37.04	2.66	$	5,129

Vested or expected to vest at April 1, 2017	1,906,548		$	35.69	4.24	$	9,937

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:



	2017			2016			2015
Volatility	24.0		%	22.8		%	22.5		%
Expected life (years)	4.9			4.9			4.9
Risk-free interest rate	1.2		%	1.4		%	1.5		%
Dividend yield	0.0		%	0.0		%	0.0		%
Fair value per option	$	7.61		$	7.40		$	7.91

Schedule of Assumptions Used, Other than Options

The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows:



	2017		2016		2015
Expected stock price volatility	26.39	%	22.27	%	20.08	%
Peer group stock price volatility	33.86	%	31.95	%	31.52	%
Correlation of returns	51.17	%	26.27	%	30.52	%

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	2017		2016		2015
Volatility	31.3	%	21.1	%	23.7	%
Expected life (months)	6		6		6
Risk-free interest rate	—	%	0.2	%	0.1	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows:



(In thousands, except per share data)	2017		2016		2015
Grant-date fair value per RSU	$	32.61	$	33.19	$	34.89
Fair value of RSUs vested	$	34.98	$	36.07	$	36.62

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	2017		2016		2015
Discount rate	0.76	%	0.72	%	0.93	%
Rate of increased salary levels	1.43	%	1.58	%	1.65	%
Expected long-term rate of return on assets	1.10	%	1.20	%	1.68	%

Schedule of Summary of Restricted Stock Units Activity

The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

A summary of RSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	380,871		$	34.33
Granted	212,105		32.61
Vested	(150,113	)	34.98
Forfeited	(101,222	)	33.70
Unvested at April 1, 2017	341,641		$	33.16

Schedule of Performance Share Unit awards

A summary of PSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	102,336		$	31.38
Granted	228,884		34.07
Vested	—		—
Forfeited	(46,595	)	30.68
Unvested at April 1, 2017	284,625		$	33.66

Schedule of Market Stock Units Award Activity

A summary of MSU activity for the fiscal year ended April 1, 2017 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Unvested at April 2, 2016	152,968		$	24.84
Granted	—		—
Vested	(116,550	)	—
Forfeited	(36,418	)	13.42
Unvested at April 1, 2017	—		$	—

EARNINGS PER SHARE ("EPS") (Tables)

12 Months Ended

Apr. 01, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



(In thousands, except per share amounts)	2017			2016			2015
Basic EPS
Net (loss) income	$	(26,268	)	$	(55,579	)	$	16,897
Weighted average shares	51,524			50,910			51,533
Basic (loss) income per share	$	(0.51	)	$	(1.09	)	$	0.33
Diluted EPS
Net (loss) income	$	(26,268	)	$	(55,579	)	$	16,897
Basic weighted average shares	51,524			50,910			51,533
Net effect of common stock equivalents	—			—			556
Diluted weighted average shares	51,524			50,910			52,089
Diluted (loss) income per share	$	(0.51	)	$	(1.09	)	$	0.32

PROPERTY, PLANT AND EQUIPMENT (Tables)

12 Months Ended

Apr. 01, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following:



(In thousands)	April 1, 2017			April 2, 2016
Land	$	7,389		$	7,905
Building and building improvements	109,933			117,132
Plant equipment and machinery	253,693			238,549
Office equipment and information technology	129,753			127,019
Haemonetics equipment	306,714			295,853
Total	807,482			786,458
Less: accumulated depreciation and amortization	(483,620		)	(448,824		)
Property, plant and equipment, net	$	323,862		$	337,634

RETIREMENT PLANS (Tables)

12 Months Ended

Apr. 01, 2017

Compensation and Retirement Disclosure [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans



(In thousands)	2017			2016			2015
Service cost	$	3,404		$	3,560		$	2,979
Interest cost on benefit obligation	287			371			686
Expected return on plan assets	(308		)	(330		)	(449		)
Actuarial loss	532			598			107
Amortization of unrecognized prior service cost	(119		)	(38		)	(29		)
Amortization of unrecognized transition obligation	37			42			45
Settlement loss recognized	289			—			—
Totals	$	4,122		$	4,203		$	3,339

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:



(In thousands)	April 1, 2017			April 2, 2016
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(37,919	)	$	(40,567	)
Service cost	(3,404		)	(3,560		)
Interest cost	(287		)	(371		)
Benefits paid	1,291			3,780
Actuarial gain	4,615			424
Employee and plan participants contribution	(2,463		)	(1,839		)
Plan amendments	—			833
Plan settlements	6,960			—
Foreign currency changes	(138		)	3,381
Benefit obligation, end of year	$	(31,345	)	$	(37,919	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	19,852		$	23,165
Company contributions	1,788			1,987
Benefits paid	(1,192		)	(3,779		)
Gain on plan assets	414			446
Employee and plan participants contributions	2,424			1,861
Plan settlements	(6,850		)	—
Foreign currency changes	849			(3,828		)
Fair value of Plan Assets, end of year	$	17,285		$	19,852
Funded Status^*	$	(14,060	)	$	(18,067	)
Unrecognized net actuarial loss	4,319			10,168
Unrecognized initial obligation	—			37
Unrecognized prior service cost	(1,019		)	(1,186		)
Net amount recognized	$	(10,760	)	$	(9,048	)
^* The unfunded status is all non-current

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in our accumulated other comprehensive loss related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, March 29, 2014	$	(4,592	)
Obligation at transition	(19		)
Actuarial loss	(6,198		)
Prior service cost	1,886
Balance as of March 28, 2015	$	(8,923	)
Obligation at transition	33
Actuarial loss	681
Prior service cost	717
Balance as of April 2, 2016	$	(7,492	)
Obligation at transition	32
Actuarial loss	5,126
Prior service cost	63
Balance as of April 1, 2017	$	(2,271	)

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows:



	2017		2016		2015
Expected stock price volatility	26.39	%	22.27	%	20.08	%
Peer group stock price volatility	33.86	%	31.95	%	31.52	%
Correlation of returns	51.17	%	26.27	%	30.52	%

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	2017		2016		2015
Volatility	31.3	%	21.1	%	23.7	%
Expected life (months)	6		6		6
Risk-free interest rate	—	%	0.2	%	0.1	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows:



(In thousands, except per share data)	2017		2016		2015
Grant-date fair value per RSU	$	32.61	$	33.19	$	34.89
Fair value of RSUs vested	$	34.98	$	36.07	$	36.62

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	2017		2016		2015
Discount rate	0.76	%	0.72	%	0.93	%
Rate of increased salary levels	1.43	%	1.58	%	1.65	%
Expected long-term rate of return on assets	1.10	%	1.20	%	1.68	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments are as follows:



(in thousands)
Fiscal 2018	$	1,396
Fiscal 2019	1,451
Fiscal 2020	1,394
Fiscal 2021	1,411
Fiscal 2022	1,617
Fiscal 2023-2027	6,869
	$	14,138

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

12 Months Ended

Apr. 01, 2017

Segment Reporting [Abstract]

Selected Information by Business Segment

Selected information by business segment is presented below:



(In thousands)	2017			2016			2015
Net revenues
Japan	$	74,695		$	84,270		$	83,547
EMEA	198,396			204,192			219,153
North America Plasma	309,718			279,803			240,705
All Other	316,771			342,249			340,427
Net revenues before foreign exchange impact	899,580			910,515			883,832
Effect of exchange rates	(13,464		)	(1,683		)	26,541
Net revenues	$	886,116		$	908,832		$	910,373



(In thousands)	2017			2016			2015
Segment operating income
Japan	$	32,906		$	38,280		$	36,843
EMEA	49,105			47,168			60,101
North America Plasma	105,253			109,220			89,092
All Other	109,296			120,562			131,471
Segment operating income	296,560			315,230			317,507
Corporate operating expenses	176,372			199,072			193,910
Effect of exchange rates	(4,772		)	3,546			13,906
Restructuring and turnaround costs	34,337			42,185			69,697
Deal amortization	27,107			28,958			30,184
Impairment of assets	73,353			97,230			—
Contingent consideration income	—			(4,727		)	(2,918		)
Operating (loss) income	$	(19,381	)	$	(43,942	)	$	40,540



(In thousands)	2017		2016		2015
Depreciation and amortization
Japan	$	827	$	774	$	767
EMEA	4,255		5,146		5,045
North America Plasma	13,022		12,944		11,229
All Other	71,629		71,047		69,012
Total depreciation and amortization (excluding impairment charges)	$	89,733	$	89,911	$	86,053



(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
Long-lived assets⁽¹⁾
Japan	$	21,412	$	33,159	$	31,810
EMEA	63,854		63,861		66,223
North America Plasma	142,164		116,001		101,272
All Other	96,432		124,613		122,643
Total long-lived assets	$	323,862	$	337,634	$	321,948
⁽¹⁾Long-lived assets are comprised of property, plant and equipment.

Long-lived assets in our principle operating regions are as follows:



(In thousands)	April 1, 2017		April 2, 2016		March 28, 2015
United States	$	241,610	$	231,744	$	208,439
Japan	1,691		2,022		1,618
Europe	12,952		18,672		27,786
Asia	34,174		40,235		39,032
Other	33,435		44,961		45,073
Total	$	323,862	$	337,634	$	321,948

Schedule of Revenues by Product Line and Geographic Regions

Management reviews revenue trends based on these business units, however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:



(In thousands)	2017		2016		2015
Plasma	410,727		381,776		352,911
Blood Center	303,890		355,108		386,147
Cell Processing	105,376		112,483		120,434
Hemostasis Management	66,123		59,465		50,881
Net revenues	$	886,116	$	908,832	$	910,373

Net revenues generated in our principle operating regions are as follows:



(In thousands)	2017		2016		2015
United States	$	522,686	$	519,440	$	494,788
Japan	79,266		81,411		88,298
Europe	166,007		187,725		215,575
Asia	109,858		111,758		102,095
Other	8,299		8,498		9,617
Total	$	886,116	$	908,832	$	910,373

RESTRUCTURING (Tables)

12 Months Ended

Apr. 01, 2017

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Transformation Costs by Type of Cost

The following summarizes the restructuring activity for the fiscal year ended April 1, 2017, April 2, 2016, and March 28, 2015, respectively:



(In thousands)	Severance and Other Employee Costs			Other Costs			Accelerated Depreciation			Asset Write Down			Total Restructuring
Balance at March 29, 2014	$	22,908		$	728		$	—		$	—		$	23,636
Costs incurred	19,879			15,362			1,326			296			36,863
Payments	(26,394		)	(15,871		)	—			—			(42,265		)
Non-cash adjustments	—			—			(1,326		)	(296		)	(1,622		)
Balance at March 28, 2015	$	16,393		$	219		$	—		$	—		$	16,612
Costs incurred	10,707			7,846			1,469			3,033			23,055
Payments	(18,348		)	(8,065		)	—			—			(26,413		)
Non-cash adjustments	—			—			(1,469		)	(3,033		)	(4,502		)
Balance at April 2, 2016	$	8,752		$	—		$	—		$	—		$	8,752
Costs incurred	19,521			1,512			—			800			21,833
Payments	(20,866		)	(1,451		)	—			—			(22,317		)
Non-cash adjustments	—			—			—			(800		)	(800		)
Balance at April 1, 2017	$	7,407		$	61		$	—		$	—		$	7,468

Restructuring and Related Costs by Segment

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs
(in thousands)	2017		2016		2015
Japan	$	819	$	9	$	258
EMEA	4,272		3,210		3,310
North America Plasma	366		—		360
All Other	16,376		19,836		32,935
Total	$	21,833	$	23,055	$	36,863

Turnaround costs
(in thousands)	2017		2016		2015
Japan	$	2	$	416	$	158
EMEA	94		961		838
North America Plasma	972		—		28
All Other	11,415		17,852		31,810
Total	$	12,483	$	19,229	$	32,834

Total restructuring and turnaround	$	34,316	$	42,284	$	69,697

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)

12 Months Ended

Apr. 01, 2017

Quarterly Financial Data [Abstract]

Schedule of Quarterly Data



(In thousands)	Three months ended
Fiscal 2017	July 2, 2016			October 1, 2016		December 31, 2016			April 1, 2017
Net revenues	$	209,956		$	220,253	$	227,841		$	228,066
Gross profit	$	91,056		$	104,248	$	101,079		$	82,111
Operating income (loss)	$	(7,881	)	$	24,794	$	21,212		$	(57,506	)
Net (loss) income	$	(10,346	)	$	19,825	$	15,393		$	(51,140	)
Per share data:
Net (loss) income:
Basic	$	(0.20	)	$	0.39	$	0.30		$	(0.98	)
Diluted	$	(0.20	)	$	0.38	$	0.30		$	(0.98	)

(In thousands)	Three months ended
Fiscal 2016	June 27, 2015			September 26, 2015		December 26, 2015			April 2, 2016
Net revenues	$	213,413		$	219,693	$	233,384		$	242,342
Gross profit	$	102,539		$	105,297	$	108,855		$	89,223
Operating (loss) income	$	3,606		$	19,179	$	(61,177	)	$	(5,550	)
Net (loss) income	$	(267	)	$	12,863	$	(59,440	)	$	(8,735	)
Per share data:
Net (loss) income:
Basic	$	(0.01	)	$	0.25	$	(1.17	)	$	(0.17	)
Diluted	$	(0.01	)	$	0.25	$	(1.17	)	$	(0.17	)

Schedule of Overstatement/(Understatement)



(In thousands)	Overstatement/(Understatement)
Three Months Ended	Operating (Loss) Income		Net (Loss) Income
April 1, 2017	(3,720	)	(4,032	)
October 1, 2016	888		1,224
April 2, 2016	(3,352	)	(2,207	)
December 26, 2015	4,776		4,584
September 26, 2015	1,193		933
June 27, 2015	1,297		219

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

12 Months Ended

Apr. 01, 2017

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended April 1, 2017 and April 2, 2016:



(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)
Other comprehensive (loss) income before reclassifications	(1,987		)	884			(3,938		)	(5,041		)
Amounts reclassified from accumulated other comprehensive loss	—			547			(8,822		)	(8,275		)
Net current period other comprehensive (loss) income	(1,987		)	1,431			(12,760		)	(13,316		)
Balance as of April 2, 2016	$	(22,499	)	$	(7,492	)	$	(5,049	)	$	(35,040	)
Other comprehensive (loss) income before reclassifications	(7,336		)	4,851			(364		)	(2,849		)
Amounts reclassified from accumulated other comprehensive loss	—			369			4,647			5,016
Net current period other comprehensive (loss) income	(7,336		)	5,220			4,283			2,167
Balance as of April 1, 2017	$	(29,835	)	$	(2,272	)	$	(766	)	$	(32,873	)

Reclassification out of Accumulated Other Comprehensive Income

The details about the amount reclassified from accumulated other comprehensive loss for the years ended April 1, 2017 and April 2, 2016 are as follows:



(In thousands)	Amounts Reclassified from Accumulated Other Comprehensive Loss						Affected Line in the Statement of (Loss) Income
Derivative instruments reclassified to income statement	Year ended April 1, 2017			Year ended April 2, 2016
Realized net (loss) gain on derivatives	$	(5,227	)	$	8,654		Net revenues, cost of goods sold, other expense, net
Income tax effect	580			168			Provision (benefit) for income taxes
Net of taxes	$	(4,647	)	$	8,822

Pension items reclassified to income statement
Realized net loss on pension assets	$	450		$	602		Other expense, net
Income tax effect	(81		)	(55		)	Provision (benefit) for income taxes
Net of taxes	$	369		$	547

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION (Details) - USD ($) $ in Millions	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016
Overstatement of Inventory Related Charges [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Overstatement amount	$ (2.4)
Overstatement of Liability, Capitalized Manufacturing Variances [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Overstatement amount		$ 3.5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Summary of Significant Accounting Pronouncements [Line Items]
Cash and cash equivalents maximum maturity period		3 months
Goodwill impairment		$ 56,989	$ 66,305
Transfer of goodwill between segments		0	0
Intangible asset impairment		4,800	25,800
Impairment charges related to the discontinuance of certain capitalized software projects	$ 6,000	4,000
Other Liabilities
VAT liabilities	1,289	4,051	1,289
Forward contracts	4,210	966	4,210
Deferred revenue	27,053	26,485	27,053
Accrued taxes	3,876	4,407	3,876
All other	30,180	27,741	30,180
Total	66,608	63,650	66,608
Other Long-Term Liabilities
Unfunded pension liability	18,067	14,060	18,067
Unrecognized tax benefit	2,283	1,627	2,283
All other	5,756	6,494	5,756
Total	$ 26,106	22,181	26,106
Advertising expense		2,500	3,900	$ 4,500
Foreign currency losses		$ 1,800	1,400	$ 1,100
Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		5 years
Minimum \| Building
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		30 years
Minimum \| Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		5 years
Minimum \| Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		3 years
Minimum \| Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		2 years
Minimum \| Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		3 years
Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		10 years
Maximum \| Building
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		40 years
Maximum \| Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		20 years
Maximum \| Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		15 years
Maximum \| Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		10 years
Maximum \| Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		7 years
SOLX Intangible Assets [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Intangible asset impairment			18,700
Intangibles Assets Identified, Global Strategic Review [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Intangible asset impairment			$ 7,100
One Customer [Member] \| Sales [Member] \| Customer Concentration Risk [Member]
Other Long-Term Liabilities
Concentration risk		14.00%	11.00%
EMEA [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Goodwill impairment		$ 0	$ 66,305
Transfer of goodwill between segments		$ 20,545	(6,390)
Intangible asset impairment			$ 6,600

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016
Product Warranties Disclosures [Abstract]
General warranty period on parts and labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the year	$ 420	$ 531
Warranty provision	400	948
Warranty spending	(644)	(1,059)
Warranty accrual as of the end of the year	$ 176	$ 420

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Apr. 01, 2017
Inventory [Line Items]
Raw materials	$ 62,062	$ 52,052
Work-in-process	13,180	10,400
Finished goods	111,786	114,477
Total Inventories	187,028	176,929
Blood Center Products [Member]
Inventory [Line Items]
Inventory charges and reserves recorded	$ 9,400	$ 11,000

GOODWILL AND INTANGIBLE ASSETS Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 210,841	$ 267,840	$ 334,310
Goodwill impairment	56,989	66,305
Intangible asset impairment	4,800	25,800
Changes in fair value of contingent consideration	0	4,727	2,918
Aggregate amortization expense	37,200	59,300	33,500
Transfer of goodwill between segments	0	0
Asset Impairments [Member]
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense	$ 4,000	25,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	19 years
EMEA [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 20,543	0	$ 72,695
Goodwill impairment	0	66,305
Intangible asset impairment		6,600
Transfer of goodwill between segments	20,545	(6,390)
All Other
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment		19,200
SOLX Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment		18,700
Changes in fair value of contingent consideration		4,900
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment		7,100
Cost of Goods Sold [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment	4,000	6,600
Impairment of Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment	$ 800	$ 19,200

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 267,840	$ 334,310
Impairment charge	(56,989)	(66,305)
Transfer of goodwill between segments	0	0
Currency translation	(10)	(165)
Goodwill, carrying amount	210,841	267,840
Japan
Goodwill [Roll Forward]
Goodwill, carrying amount	24,883	24,899
Impairment charge	0	0
Transfer of goodwill between segments	0	0
Currency translation	(3)	(16)
Goodwill, carrying amount	24,880	24,883
EMEA [Member]
Goodwill [Roll Forward]
Goodwill, carrying amount	0	72,695
Impairment charge	0	(66,305)
Transfer of goodwill between segments	20,545	(6,390)
Currency translation	(2)	0
Goodwill, carrying amount	20,543	0
North America Plasma [Member]
Goodwill [Roll Forward]
Goodwill, carrying amount	26,415	26,415
Impairment charge	0	0
Transfer of goodwill between segments	0	0
Currency translation	0	0
Goodwill, carrying amount	26,415	26,415
All Other
Goodwill [Roll Forward]
Goodwill, carrying amount	216,542	210,301
Impairment charge	(56,989)	0
Transfer of goodwill between segments	(20,545)	6,390
Currency translation	(5)	(149)
Goodwill, carrying amount	$ 139,003	$ 216,542

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Amortizable:
Gross Carrying Amount	$ 378,736	$ 378,343
Accumulated Amortization	215,772	190,816
Net	162,964	187,527
Non-amortizable intangibles	14,576	16,931
Fiscal 2018	31,495
Fiscal 2019	30,089
Fiscal 2020	28,091
Fiscal 2021	26,190
Fiscal 2022	25,485
In-process software development
Amortizable:
Non-amortizable intangibles	12,743	14,427
In-process patents
Amortizable:
Non-amortizable intangibles	1,833	2,504
Patents
Amortizable:
Gross Carrying Amount	9,183	8,545
Accumulated Amortization	8,043	7,542
Net	1,140	1,003
Capitalized software
Amortizable:
Gross Carrying Amount	49,948	40,488
Accumulated Amortization	21,563	14,791
Net	28,385	25,697
Other developed technology
Amortizable:
Gross Carrying Amount	117,712	126,142
Accumulated Amortization	72,594	73,475
Net	45,118	52,667
Customer contracts and related relationships
Amortizable:
Gross Carrying Amount	194,876	196,085
Accumulated Amortization	108,073	89,804
Net	86,803	106,281
Trade names
Amortizable:
Gross Carrying Amount	7,017	7,083
Accumulated Amortization	5,499	5,204
Net	$ 1,518	$ 1,879

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) $ in Thousands	12 Months Ended
	Apr. 01, 2017 USD ($)	Apr. 02, 2016 USD ($)	Mar. 28, 2015 USD ($)	Dec. 21, 2012 USD ($) swap
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US	41.00%
Maturity period for foreign currency contracts (in years)	1 year
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding	$ 68,400	$ 107,400
Designated as Hedging Instrument [Member] \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) on cash flow hedge in earnings	(4,600)	8,800	$ 6,500
Designated as Hedging Instrument [Member] \| Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps held \| swap				2
Derivative, Notional Amount	50,000			$ 250,000
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	0
Non-designated foreign currency hedge contracts outstanding	55,400	48,800
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] \| Designated as Hedging Instrument [Member] \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (524)	$ (3,900)	$ 12,200

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (524)	$ (3,900)	$ 12,200
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	(4,647)
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	636
Designated as Hedging Instrument [Member] \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument [Member] \| Interest Rate Swap \| Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	160
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	0
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ 221

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Designated as Hedging Instrument [Member]
Derivative Assets:
Derivative Assets	$ 1,927	$ 427
Derivative Liabilities:
Derivative Liabilities	966	4,210
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	1,645	335
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	894	3,910
Designated as Hedging Instrument [Member] \| Interest Rate Swap \| Other Current Assets
Derivative Assets:
Derivative Assets	64	0
Designated as Hedging Instrument [Member] \| Interest Rate Swap \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	0	154
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	218	$ 92
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 72

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Assets
Money market funds	$ 80,676	$ 72,491
Designated interest rate swaps	64
Assets, Fair Value Disclosure, Total	82,603	72,918
Liabilities
Interest rate swap		154
Liabilities, Fair Value Disclosure, Total	966	4,210
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	80,676	72,491
Designated interest rate swaps	0
Assets, Fair Value Disclosure, Total	80,676	72,491
Liabilities
Interest rate swap		0
Liabilities, Fair Value Disclosure, Total	0	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0	0
Designated interest rate swaps	64
Assets, Fair Value Disclosure, Total	1,927	427
Liabilities
Interest rate swap		154
Liabilities, Fair Value Disclosure, Total	966	4,210
Designated as Hedging Instrument [Member]
Assets
Foreign currency hedge contracts	1,645	335
Liabilities
Foreign currency hedge contracts	894	3,910
Designated as Hedging Instrument [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Foreign currency hedge contracts	0	0
Liabilities
Foreign currency hedge contracts	0	0
Designated as Hedging Instrument [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Foreign currency hedge contracts	1,645	335
Liabilities
Foreign currency hedge contracts	894	3,910
Not Designated as Hedging Instrument [Member]
Assets
Foreign currency hedge contracts	218	92
Liabilities
Foreign currency hedge contracts	72	146
Not Designated as Hedging Instrument [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Foreign currency hedge contracts	0	0
Liabilities
Foreign currency hedge contracts	0	0
Not Designated as Hedging Instrument [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Foreign currency hedge contracts	218	92
Liabilities
Foreign currency hedge contracts	$ 72	$ 146

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Debt Instrument [Line Items]
Long-term debt	$ 315,810
Less current portion	(61,022)	$ (43,471)
Long term debt	253,625	364,529
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt	314,218	406,175
Bank loans and other borrowings
Debt Instrument [Line Items]
Long-term debt	$ 429	$ 1,825

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details)		12 Months Ended
NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details)	Aug. 01, 2012 USD ($)	Apr. 01, 2017 USD ($) tranche	Apr. 02, 2016 USD ($)	Mar. 28, 2015 USD ($)	Jun. 30, 2014 USD ($)
Debt Instrument [Line Items]
Number of tranches \| tranche		4
Interest paid		$ 7,850,000	$ 8,511,000	$ 8,497,000
Long-term debt		315,810,000
Term Loan
Debt Instrument [Line Items]
Face amount of debt		315,400,000
Basis spread on variable rate	1.25%
Amount outstanding		$ 315,400,000
Effective interest rate		2.25%
Debt discount		$ (1,200,000)
Term Loan \| Pall Corporation [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 475,000,000
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt		314,218,000	$ 406,175,000
Revolving Credit Facility
Debt Instrument [Line Items]
Face amount of debt	$ 50,000,000
Amount outstanding		$ 0
Maximum borrowing capacity					$ 100,000,000
Consolidated total leverage ratio		3.0
Consolidated interest coverage ratio		4.0
Commitment fee		0.20%
Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee		0.175%
Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee		0.30%
Credit Agreement
Debt Instrument [Line Items]
Adjusted libor rounding percentage	0.625%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Effective interest rate		2.25%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) $ in Thousands	Apr. 01, 2017 USD ($)
Debt Instrument [Line Items]
2018	$ 61,810
2019	194,583
2020	59,382
2021	28
2022	2
Thereafter	5
Long-term debt	315,810
Credit Facilities
Debt Instrument [Line Items]
2018	61,654
2019	194,445
2020	59,282
2021	0
2022	0
Thereafter	0
Long-term debt	315,381
Bank loans and other borrowings
Debt Instrument [Line Items]
2018	156
2019	138
2020	100
2021	28
2022	2
Thereafter	5
Long-term debt	$ 429

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Income Taxes [Line Items]
Foregin source income	$ 17,248	$ (34,890)	$ 48,430
Valuation allowance	13,505	5,194	$ 8,524
Unremitted earnings	1,065	700
Tax credit carry-forward, net	$ 17,852	$ 16,191
Income tax provision	4.40%	(4.00%)	45.80%
Unremitted earnings which are not indefinitely reinvested	$ 8,400
Amount of unremitted earnings affecting tax rate	100
Undistributed foreign earnings of subsidiaries	$ 233,000
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
Unremitted earnings	$ 330	$ 735	$ 0
(Benefit) provision for income taxes	(1,208)	2,163	14,268
Unrecognized tax benefits	3,370	2,523	7,070	$ 5,604
Unrecognized tax benefits that will impact effective tax rate	1,500	600	2,000
Unrecognized tax positions possible change in the next twelve months	1,500
Unrecognized tax benefits increases	800
Unrecognized tax benefits, increase resulting from workforce reduction	1,300
Accrued interest and penalties	200	400
Accrued interest on income tax benefit	200	$ 300	$ 300
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Valuation allowance	1,600
Operating loss carry-forwards	23,300
Tax credit carry-forward, net	15,100
Domestic Tax Authority [Member] \| Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	4,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	33,000
Tax credit carry-forward, net	4,200
State and Local Jurisdiction [Member] \| Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	5,200
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	$ 19,200
Puerto Rico
Income Taxes [Line Items]
Tax grant or holiday term	15 years
Switzerland
Income Taxes [Line Items]
Tax grant or holiday term	10 years
Malaysia
Income Taxes [Line Items]
Tax grant or holiday term	10 years

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Income Tax Disclosure [Abstract]
Domestic	$ (44,724)	$ (18,526)	$ (17,265)
Foreign	17,248	(34,890)	48,430
(Loss) income before (benefit) provision for income taxes	$ (27,476)	$ (53,416)	$ 31,165

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Current
Federal	$ (1,424)	$ 12	$ 3,526
State	436	(660)	898
Foreign	6,580	3,842	5,614
Total current	5,592	3,194	10,038
Deferred
Federal	(8,711)	3,532	1,227
State	(953)	319	3,215
Foreign	2,864	(4,882)	(212)
Total deferred	(6,800)	(1,031)	4,230
Total	$ (1,208)	$ 2,163	$ 14,268

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Apr. 02, 2016
Income Tax Disclosure [Abstract]
Depreciation	$ 934	$ 1,749
Amortization of intangibles	1,150	4,417
Inventory	7,419	7,607
Hedging	0	382
Accruals, reserves and other deferred tax assets	13,907	12,590
Net operating loss carry-forward	11,742	13,484
Stock based compensation	6,014	9,622
Tax credit carry-forward, net	17,852	16,191
Gross deferred tax assets	59,018	66,042
Total deferred tax liabilities	(25,872)	(24,297)
Total deferred tax assets (after valuation allowance)	33,146	41,745
Depreciation	(30,422)	(28,972)
Amortization of goodwill and intangibles	(7,732)	(23,626)
Unremitted earnings	(1,065)	(700)
Other deferred tax liabilities	(2,053)	(2,769)
Other deferred tax liabilities	(41,272)	(56,067)
Net deferred tax liabilities	$ (8,126)	$ (14,322)

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ (9,616)	$ (18,695)	$ 10,907
Tax at federal statutory rate	35.00%	35.00%	35.00%
Difference between U.S. and foreign tax	$ 137	$ 10,645	$ (6,929)
Difference between U.S. and foreign tax	(0.50%)	(19.90%)	(22.20%)
State income taxes net of federal benefit	$ (495)	$ 134	$ (818)
State income taxes net of federal benefit	1.80%	(0.30%)	(2.60%)
Change in uncertain tax positions	$ 862	$ (1,820)	$ (1,762)
Change in uncertain tax positions	(3.10%)	3.40%	(5.70%)
Unremitted earnings	$ 330	$ 735	$ 0
Unremitted earnings	(1.20%)	(1.40%)	(0.00%)
Deferred statutory rate changes	$ (383)	$ (2,653)	$ 0
Deferred statutory rate changes	1.40%	5.00%	0.00%
Non-deductible goodwill impairment	$ 3,703	$ 2,861	$ 0
Non-deductible goodwill impairment	(13.50%)	(5.40%)	(0.00%)
Non-deductible expenses	$ 896	$ 1,491	$ 1,237
Non-deductible expenses	(3.20%)	(2.80%)	4.00%
Research credits	$ (561)	$ (672)	$ (1,000)
Research credits	2.00%	1.30%	(3.20%)
Tax amortization of goodwill	$ (10,564)	$ 4,185	$ 3,826
Tax amortization of goodwill	38.40%	(7.80%)	12.30%
Valuation allowance	$ 13,505	$ 5,194	$ 8,524
Valuation allowance	(49.20%)	(9.70%)	27.40%
Other, net	$ 978	$ 758	$ 283
Other, net	(3.50%)	(1.40%)	0.80%
Total	$ (1,208)	$ 2,163	$ 14,268
Income tax (benefit) provision	4.40%	(4.00%)	45.80%

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 2,523	$ 7,070	$ 5,604
Additions for tax positions of prior years	1,279	340	3,234
Reductions of tax positions	(29)	(4,158)	0
Settlements with taxing authorities	0	0	(338)
Closure of statute of limitations	(403)	(729)	(1,430)
Ending Balance	$ 3,370	$ 2,523	$ 7,070

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) $ in Thousands	Apr. 01, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 4,298
2019	2,966
2020	1,906
2021	1,722
2022	1,623
Thereafter	7,031
Operating Leases, Future Minimum Payments Due	$ 19,546

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	1 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jul. 31, 2016	Apr. 30, 2013	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Loss Contingencies [Line Items]
Rent expense			$ 6,200,000	$ 6,800,000	$ 6,300,000
Product Recall
Loss Contingencies [Line Items]
Damages claimed			14,200,000
Product recall expense			7,100,000
Product Recall \| Minimum
Loss Contingencies [Line Items]
Estimate of possible loss			3,400,000
Product Recall \| Maximum
Loss Contingencies [Line Items]
Estimate of possible loss			14,200,000
Product Recall \| Customer Returns and Inventory Reserves [Member]
Loss Contingencies [Line Items]
Product recall expense			3,700,000
Product Recall \| Customer Claims [Member]
Loss Contingencies [Line Items]
Product recall expense			3,400,000
Insurance settlements receivable			2,900,000
Product Recall \| Inventories [Member]
Loss Contingencies [Line Items]
Product recall expense			1,100,000
Product Recall \| Sales [Member]
Loss Contingencies [Line Items]
Product recall expense			2,500,000
Product Recall \| Freight Expense [Member]
Loss Contingencies [Line Items]
Product recall expense			100,000
Italian Employment Litigation [Member]
Loss Contingencies [Line Items]
Damages claimed			4,400,000
Amount accrued			0
SOLX Arbitration [Member]
Loss Contingencies [Line Items]
Damages claimed	$ 17,000,000
Amount accrued			$ 0
Consideration paid		$ 24,000,000
Contingent milestone payment		3,000,000
Maximum future royalty payments		$ 14,000,000
Royalty Term		10 years

CAPITAL STOCK (Narrative) (Details)	12 Months Ended
CAPITAL STOCK (Narrative) (Details)	Apr. 01, 2017 USD ($) member $ / shares shares	Apr. 02, 2016 USD ($) period $ / shares shares	Mar. 28, 2015 USD ($) $ / shares	Mar. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	5,045,728
Income tax benefit recognized related to stock-based compensation \| $	$ 0	$ 4,500,000
Excess cash tax benefit classified as a financing cash inflow \| $	$ 0	$ 1,600,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	3,200,000
Number of purchase periods (in purchase periods) \| period		2
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares	$ 7.79	$ 7.80	$ 7.09
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6 months	6 months	6 months
Employee Stock Purchase Plan [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	2.00%
Employee Stock Purchase Plan [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	15.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	2,038,795	2,951,183
Award expiration period	7 years
Total intrinsic value of options exercised \| $	$ 8,300,000	$ 4,500,000	$ 5,600,000
Total unrecognized compensation cost related to non vested awards \| $	$ 4,900,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	3 years 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Stock Options [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Stock Options [Member] \| Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	341,641	380,871
Total unrecognized compensation cost related to non vested awards \| $	$ 8,400,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 10 months 13 days
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares	$ 32.61	$ 33.19	$ 34.89
Restricted Stock Units (RSUs) [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Restricted Stock Units (RSUs) [Member] \| Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	569,250,000
Equity instruments other than options outstanding (in shares)	284,625	102,336
Total unrecognized compensation cost related to non vested awards \| $	$ 7,800,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 3 months 15 days
Award performance period	3 years
Performance shares target, percentage	100.00%
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares	$ 34.07	$ 29.20	$ 35.09
Performance Share Units (PSUs) [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	0.00%
Performance Share Units (PSUs) [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	200.00%
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	0	152,968
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares	$ 0.00
Market Stock Units [Member] \| Minimum Threshold Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price \| $ / shares	$ 50
Incentive Compensation Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of members on board of directors (in board members) \| member	3
Maximum number of shares available for award (in shares)	19,824,920
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.02
Incentive Compensation Plan 2005 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	500,000
Number of options counted against maximum number of award shares for every share option issued (in shares)	1

CAPITAL STOCK (Schedule of Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 9,150	$ 6,949	$ 14,095
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	6,894	5,183	11,251
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	1,549	1,060	1,706
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 707	$ 706	$ 1,138

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	2,951,183
Options Outstanding, (in shares), Granted	501,127
Options Outstanding, (in shares), Exercised	(1,083,824)
Options Outstanding, (in shares), Forfeited	(329,691)
Options Outstanding, (in shares), Ending Balance	2,038,795	2,951,183
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 33.59
Weighted Average Exercise Price (in dollars per share), Granted	32.47
Weighted Average Exercise Price (in dollars per share), Exercised	28.79
Weighted Average Exercise Price (in dollars per share), Forfeited	35.95
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 35.51	$ 33.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	3 years 10 months 17 days	3 years 4 months 2 days
Aggregate Intrinsic Value, Balance	$ 10,963	$ 9,684
Options Outstanding, (in shares), Exercisable and End of Period	1,284,592
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 37.04
Weighted Average Remaining Life, Exercisable at End of Period	2 years 7 months 28 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 5,129
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	1,906,548
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 35.69
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	4 years 2 months 27 days
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 9,937

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value) (Details) - $ / shares	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015	Mar. 30, 2013
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility		31.30%	21.10%	23.70%
Expected term		6 months	6 months	6 months
Risk-free interest rate		0.00%	0.20%	0.10%
Dividend Yield		0.00%	0.00%	0.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	24.00%	22.80%	22.50%
Expected term	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	1.20%	1.40%	1.50%
Dividend Yield	0.00%	0.00%	0.00%
Fair value per option (in dollars per share)	$ 7.61	$ 7.40	$ 7.91
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value (in dollars per share), Granted	32.61	33.19	34.89
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 34.98	$ 36.07	$ 36.62
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	26.39%	22.27%	20.08%
Peer group stock price volatility	33.86%	31.95%	31.52%
Correlation of returns	51.17%	26.27%	30.52%
Weighted Average Grant Date Fair Value (in dollars per share), Granted	$ 34.07	$ 29.20	$ 35.09
Weighted Average Grant Date Fair Value (in dollars per share), Vested	0.00
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value (in dollars per share), Granted	0.00
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 0.00

CAPITAL STOCK (Schedule of Summary of Equity Awards other than Options Activity) (Details) - $ / shares	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	380,871
Shares, Granted (in shares)	212,105
Shares, Vested (in shares)	(150,113)
Shares, Forfeited (in shares)	(101,222)
Shares, Ending Balance (in shares)	341,641	380,871
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 34.33
Weighted Average Grant Date Fair Value (in dollars per share), Granted	32.61	$ 33.19	$ 34.89
Weighted Average Grant Date Fair Value (in dollars per share), Vested	34.98	36.07	36.62
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	33.70
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 33.16	$ 34.33
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	102,336
Shares, Granted (in shares)	228,884
Shares, Vested (in shares)	0
Shares, Forfeited (in shares)	(46,595)
Shares, Ending Balance (in shares)	284,625	102,336
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 31.38
Weighted Average Grant Date Fair Value (in dollars per share), Granted	34.07	$ 29.20	$ 35.09
Weighted Average Grant Date Fair Value (in dollars per share), Vested	0.00
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	30.68
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 33.66	$ 31.38
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	152,968
Shares, Granted (in shares)	0
Shares, Vested (in shares)	(116,550)
Shares, Forfeited (in shares)	(36,418)
Shares, Ending Balance (in shares)	0	152,968
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 24.84
Weighted Average Grant Date Fair Value (in dollars per share), Granted	0.00
Weighted Average Grant Date Fair Value (in dollars per share), Vested	0.00
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	13.42
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 0.00	$ 24.84

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 01, 2017	Dec. 31, 2016	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Basic EPS
Net (loss) income	$ (51,140)	$ 15,393	$ 19,825	$ (10,346)	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (26,268)	$ (55,579)	$ 16,897
Basic weighted average shares (in shares)									51,524	50,910	51,533
Basic (loss) income per share (in dollars per share)	$ (0.98)	$ 0.30	$ 0.39	$ (0.20)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.51)	$ (1.09)	$ 0.33
Diluted EPS
Net (loss) income	$ (51,140)	$ 15,393	$ 19,825	$ (10,346)	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (26,268)	$ (55,579)	$ 16,897
Basic weighted average shares (in shares)									51,524	50,910	51,533
Net effect of common stock equivalents (in shares)									0	0	556
Diluted weighted average shares (in shares)									51,524	50,910	52,089
Diluted (loss) income per share (in dollars per share)	$ (0.98)	$ 0.30	$ 0.38	$ (0.20)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.51)	$ (1.09)	$ 0.32
Stock options and restricted share units excluded from computation of weighted average shares outstanding (in shares)											1,600

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Property, Plant and Equipment [Line Items]
Total	$ 807,482	$ 786,458
Less: accumulated depreciation and amortization	(483,620)	(448,824)
Net property, plant and equipment	323,862	337,634
Impairment of property, plant and equipment	13,300	9,100
Depreciation expense	66,500	56,800	$ 52,600
Asset Impairments [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	10,000	800
Impairment of Assets [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	800	6,900
Cost of Goods Sold [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	12,500	2,200
Land
Property, Plant and Equipment [Line Items]
Total	7,389	7,905
Building and building improvements
Property, Plant and Equipment [Line Items]
Total	109,933	117,132
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Total	253,693	238,549
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Total	129,753	127,019
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Total	306,714	295,853
Americas Blood Center and Hospital [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	10,600	3,000
North America Plasma [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	1,700
EMEA [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	$ 1,000	$ 6,100

RETIREMENT PLANS (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation, plan funded by company	$ 8,800	$ 8,700
Benefit obligation	(31,345)	(37,919)	$ (40,567)
Accumulated benefit obligation	28,700	36,400
Fair value of plan assets	17,285	19,852	23,165
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	200
Reinsurance contracts asset value	5,400	5,400
Subsidiaries [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	800	800	1,000
Savings Plus Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 5,100	$ 5,400	$ 5,800

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 3,404	$ 3,560	$ 2,979
Interest cost on benefit obligation	287	371	686
Expected return on plan assets	(308)	(330)	(449)
Actuarial loss	532	598	107
Amortization of unrecognized prior service cost	(119)	(38)	(29)
Amortization of unrecognized transition obligation	37	42	45
Settlement loss recognized	289	0	0
Totals	$ 4,122	$ 4,203	$ 3,339

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (37,919)	$ (40,567)
Service cost	(3,404)	(3,560)	$ (2,979)
Interest cost	(287)	(371)	(686)
Benefits paid	1,291	3,780
Actuarial gain	4,615	424
Employee and plan participants contribution	(2,463)	(1,839)
Plan amendments	0	833
Plan settlements	6,960	0
Foreign currency changes	(138)	3,381
Benefit obligation, end of year	(31,345)	(37,919)	(40,567)
Change in Plan Assets:
Fair value of plan assets, beginning of year	19,852	23,165
Company contributions	1,788	1,987
Benefits paid	(1,192)	(3,779)
Gain on plan assets	414	446
Employee and plan participants contributions	2,424	1,861
Plan settlements	(6,850)	0
Foreign currency changes	849	(3,828)
Fair value of Plan Assets, end of year	17,285	19,852	$ 23,165
Funded Status	(14,060)	(18,067)
Unrecognized net actuarial loss	4,319	10,168
Unrecognized initial obligation	0	37
Unrecognized prior service cost	(1,019)	(1,186)
Net amount recognized	$ (10,760)	$ (9,048)

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (7,492)	$ (8,923)	$ (4,592)
Obligation at transition	32	33	(19)
Actuarial loss	5,126	681	(6,198)
Prior service cost	63	717	1,886
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (2,271)	$ (7,492)	$ (8,923)

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Compensation and Retirement Disclosure [Abstract]
Discount rate	0.76%	0.72%	0.93%
Rate of increased salary levels	1.43%	1.58%	1.65%
Expected long-term rate of return on assets	1.10%	1.20%	1.68%

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Apr. 01, 2017 USD ($)
Expected Benefit Payments
Fiscal 2018	$ 1,396
Fiscal 2019	1,451
Fiscal 2020	1,394
Fiscal 2021	1,411
Fiscal 2022	1,617
Fiscal 2023-2027	6,869
Total	$ 14,138

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details)	3 Months Ended								12 Months Ended
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details)	Apr. 01, 2017 USD ($)	Dec. 31, 2016 USD ($)	Oct. 01, 2016 USD ($)	Jul. 02, 2016 USD ($)	Apr. 02, 2016 USD ($)	Dec. 26, 2015 USD ($)	Sep. 26, 2015 USD ($)	Jun. 27, 2015 USD ($)	Apr. 01, 2017 USD ($) unit	Apr. 02, 2016 USD ($)	Mar. 28, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of business units \| unit									4
Net revenues before foreign exchange impact									$ 899,580,000	$ 910,515,000	$ 883,832,000
Effect of exchange rates									(13,464,000)	(1,683,000)	26,541,000
Net revenues	$ 228,066,000	$ 227,841,000	$ 220,253,000	$ 209,956,000	$ 242,342,000	$ 233,384,000	$ 219,693,000	$ 213,413,000	886,116,000	908,832,000	910,373,000
Segment operating income									296,560,000	315,230,000	317,507,000
Corporate operating expenses									176,372,000	199,072,000	193,910,000
Effect of exchange rates									(4,772,000)	3,546,000	13,906,000
Restructuring and turnaround costs									34,337,000	42,185,000	69,697,000
Deal amortization									27,107,000	28,958,000	30,184,000
Impairment of assets									73,353,000	97,230,000	0
Contingent consideration income									0	(4,727,000)	(2,918,000)
Operating (loss) income	(57,506,000)	$ 21,212,000	$ 24,794,000	$ (7,881,000)	(5,550,000)	$ (61,177,000)	$ 19,179,000	$ 3,606,000	(19,381,000)	(43,942,000)	40,540,000
Depreciation and amortization									89,733,000	89,911,000	86,053,000
Long-lived assets	323,862,000				337,634,000				323,862,000	337,634,000	321,948,000
Plasma [Member]
Segment Reporting Information [Line Items]
Net revenues									410,727,000	381,776,000	352,911,000
Blood center disposables
Segment Reporting Information [Line Items]
Net revenues									303,890,000	355,108,000	386,147,000
Cell Processing [Member]
Segment Reporting Information [Line Items]
Net revenues									105,376,000	112,483,000	120,434,000
Hemostasis Management [Member]
Segment Reporting Information [Line Items]
Net revenues									66,123,000	59,465,000	50,881,000
United States
Segment Reporting Information [Line Items]
Net revenues									522,686,000	519,440,000	494,788,000
Long-lived assets	241,610,000				231,744,000				241,610,000	231,744,000	208,439,000
Japan
Segment Reporting Information [Line Items]
Net revenues									79,266,000	81,411,000	88,298,000
Long-lived assets	1,691,000				2,022,000				1,691,000	2,022,000	1,618,000
Europe
Segment Reporting Information [Line Items]
Net revenues									166,007,000	187,725,000	215,575,000
Long-lived assets	12,952,000				18,672,000				12,952,000	18,672,000	27,786,000
Asia
Segment Reporting Information [Line Items]
Net revenues									109,858,000	111,758,000	102,095,000
Long-lived assets	34,174,000				40,235,000				34,174,000	40,235,000	39,032,000
Other
Segment Reporting Information [Line Items]
Net revenues									8,299,000	8,498,000	9,617,000
Long-lived assets	33,435,000				44,961,000				33,435,000	44,961,000	45,073,000
Japan
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact									74,695,000	84,270,000	83,547,000
Segment operating income									32,906,000	38,280,000	36,843,000
Depreciation and amortization									827,000	774,000	767,000
Long-lived assets	21,412,000				33,159,000				21,412,000	33,159,000	31,810,000
EMEA [Member]
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact									198,396,000	204,192,000	219,153,000
Segment operating income									49,105,000	47,168,000	60,101,000
Depreciation and amortization									4,255,000	5,146,000	5,045,000
Long-lived assets	63,854,000				63,861,000				63,854,000	63,861,000	66,223,000
North America Plasma [Member]
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact									309,718,000	279,803,000	240,705,000
Segment operating income									105,253,000	109,220,000	89,092,000
Depreciation and amortization									13,022,000	12,944,000	11,229,000
Long-lived assets	142,164,000				116,001,000				142,164,000	116,001,000	101,272,000
All Other
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact									316,771,000	342,249,000	340,427,000
Segment operating income									109,296,000	120,562,000	131,471,000
Depreciation and amortization									71,629,000	71,047,000	69,012,000
Long-lived assets	$ 96,432,000				$ 124,613,000				$ 96,432,000	$ 124,613,000	$ 122,643,000

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring costs recorded	$ 21,833	$ 23,055	$ 36,863
Restructuring charges in next twelve months	7,100
Restructuring liability	7,468	8,752	16,612	$ 23,636
Turnaround costs	12,483	19,229	32,834
Total restructuring and turnaround	34,316	42,284	69,697
Severance and other employee costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs recorded	19,521	10,707	19,879
Restructuring liability	7,407	8,752	16,393	22,908
Other costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs recorded	1,512	7,846	15,362
Restructuring liability	61	$ 0	$ 219	$ 728
Global Strategic Review [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	26,000
Expected savings	40,000
Restructuring costs incurred	28,700
Prior Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring and turnaround	$ 5,600

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 8,752	$ 16,612	$ 23,636
Cost Incurred	21,833	23,055	36,863
Payments	(22,317)	(26,413)	(42,265)
Non-cash adjustments	(800)	(4,502)	(1,622)
Ending Balance	7,468	8,752	16,612
Turnaround costs	12,483	19,229	32,834
Total restructuring and turnaround	34,316	42,284	69,697
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Beginning Balance	8,752	16,393	22,908
Cost Incurred	19,521	10,707	19,879
Payments	(20,866)	(18,348)	(26,394)
Non-cash adjustments	0	0	0
Ending Balance	7,407	8,752	16,393
Other costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0	219	728
Cost Incurred	1,512	7,846	15,362
Payments	(1,451)	(8,065)	(15,871)
Non-cash adjustments	0	0	0
Ending Balance	61	0	219
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Cost Incurred	0	1,469	1,326
Payments	0	0	0
Non-cash adjustments	0	(1,469)	(1,326)
Ending Balance	0	0	0
Asset write-down
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Cost Incurred	800	3,033	296
Payments	0	0	0
Non-cash adjustments	(800)	(3,033)	(296)
Ending Balance	0	0	0
Japan
Restructuring Reserve [Roll Forward]
Cost Incurred	819	9	258
Turnaround costs	2	416	158
EMEA [Member]
Restructuring Reserve [Roll Forward]
Cost Incurred	4,272	3,210	3,310
Turnaround costs	94	961	838
North America Plasma [Member]
Restructuring Reserve [Roll Forward]
Cost Incurred	366	0	360
Turnaround costs	972	0	28
All Other
Restructuring Reserve [Roll Forward]
Cost Incurred	16,376	19,836	32,935
Turnaround costs	$ 11,415	$ 17,852	$ 31,810

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Capitalization of Software and Development Costs [Abstract]
Capitalized software development costs for ongoing initiatives		$ 11.0	$ 17.0
Software costs capitalized, net	$ 54.9	62.7	54.9
Total costs capitalized related to in process software development initiatives	14.4	12.7	14.4
Interest costs capitalized		0.3	0.2
Capitalized costs amortized (placed into service)		9.5	8.7
Amortization of capitalized software development cost expense		9.7	$ 10.9	$ 3.2
Impairment charges related to the discontinuance of certain capitalized software projects	$ 6.0	$ 4.0

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Apr. 01, 2017	Dec. 31, 2016	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Quarterly Financial Data [Abstract]
Net revenues	$ 228,066,000	$ 227,841,000	$ 220,253,000	$ 209,956,000	$ 242,342,000	$ 233,384,000	$ 219,693,000	$ 213,413,000	$ 886,116,000	$ 908,832,000	$ 910,373,000
Gross profit	82,111,000	101,079,000	104,248,000	91,056,000	89,223,000	108,855,000	105,297,000	102,539,000	378,494,000	405,914,000	434,418,000
Operating income (loss)	(57,506,000)	21,212,000	24,794,000	(7,881,000)	(5,550,000)	(61,177,000)	19,179,000	3,606,000	(19,381,000)	(43,942,000)	40,540,000
Net (loss) income	$ (51,140,000)	$ 15,393,000	$ 19,825,000	$ (10,346,000)	$ (8,735,000)	$ (59,440,000)	$ 12,863,000	$ (267,000)	$ (26,268,000)	$ (55,579,000)	$ 16,897,000
Per share data:
Basic (loss) income per share (in dollars per share)	$ (0.98)	$ 0.30	$ 0.39	$ (0.20)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.51)	$ (1.09)	$ 0.33
Diluted (loss) income per share (in dollars per share)	$ (0.98)	$ 0.30	$ 0.38	$ (0.20)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.51)	$ (1.09)	$ 0.32
Understatement of Operating Loss	$ (3,720,000)				$ (3,352,000)
Overstatement of Operating Income			$ 888,000			$ 4,776,000	$ 1,193,000	$ 1,297,000
Understatement of Net Loss	$ (4,032,000)				$ (2,207,000)
Overstatement of Net Income			$ 1,224,000			$ 4,584,000	$ 933,000	$ 219,000

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	$ (35,040)	$ (21,724)
Other comprehensive income before reclassifications	(2,849)	(5,041)
Amounts reclassified from Accumulated Other Comprehensive Income	5,016	(8,275)
Other comprehensive income (loss)	2,167	(13,316)	$ (23,134)
Accumulated Other Comprehensive Income, Balance	(32,873)	(35,040)	(21,724)
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(22,499)	(20,512)
Other comprehensive income before reclassifications	(7,336)	(1,987)
Amounts reclassified from Accumulated Other Comprehensive Income	0	0
Other comprehensive income (loss)	(7,336)	(1,987)
Accumulated Other Comprehensive Income, Balance	(29,835)	(22,499)	(20,512)
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(7,492)	(8,923)
Other comprehensive income before reclassifications	4,851	884
Amounts reclassified from Accumulated Other Comprehensive Income	369	547
Other comprehensive income (loss)	5,220	1,431
Accumulated Other Comprehensive Income, Balance	(2,272)	(7,492)	(8,923)
Net Unrealized Gain/loss on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(5,049)	7,711
Other comprehensive income before reclassifications	(364)	(3,938)
Amounts reclassified from Accumulated Other Comprehensive Income	4,647	(8,822)
Other comprehensive income (loss)	4,283	(12,760)
Accumulated Other Comprehensive Income, Balance	$ (766)	$ (5,049)	$ 7,711

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 2) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 01, 2017	Dec. 31, 2016	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									$ (8,095)	$ (9,474)	$ (9,375)
Income tax effect									1,208	(2,163)	(14,268)
Net (loss) income	$ (51,140)	$ 15,393	$ 19,825	$ (10,346)	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	(26,268)	(55,579)	$ 16,897
Net Unrealized Gain/loss on Derivatives \| Amounts Reclassified from Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									(5,227)	8,654
Income tax effect									580	168
Net (loss) income									(4,647)	8,822
Defined benefit plans \| Amounts Reclassified from Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									450	602
Income tax effect									(81)	(55)
Net (loss) income									$ 369	$ 547

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] - SEBRA Sealers Product Line [Member] $ in Millions	Apr. 27, 2017 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business	$ 9
Transition period	90 days
Preliminary pre-tax gain expected	$ 8

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2017	Apr. 02, 2016	Mar. 28, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Fiscal Year	$ 2,253	$ 1,749	$ 1,676
Charged to Costs and Expenses	103	728	399
Write-Offs (Net of Recoveries)	172	(224)	(326)
Balance at End of Fiscal Year	$ 2,184	$ 2,253	$ 1,749